




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|---|
| (51) International Patent Classification 6 : C12N 15/19, 15/79, C07K 14/52, A61K 38/19, C12N 1/19, 5/10 | | A1 | (11) International Publication Number: WO 96/17062 (43) International Publication Date: 6 June 1996 (06.06.96) |
| (21) International Application Number: PCT/US95/14929 (22) International Filing Date: 15 November 1995 (15.11.95) (30) Priority Data: 08/346,999 30 November 1994 (30.11.94) US (71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US). (72) Inventors: BUDDLE, Michele, M.; 32924 S.E. 46, Fall City, WA 98034 (US). DOWNEY, William; 6544 11th Avenue N.W., Seattle, WA 98117 (US). FOSTER, Donald, C.; 3002 N.E. 181st Street, Seattle, WA 98155 (US). FORSTROM, John, W.; 7559 30th Avenue N.E., Seattle, WA 98115 (US). LOK, Si; 806 N.W. 52nd, Seattle, WA 98107 (US). OSBORN, Sherri, G.; 8835 Ashworth Avenue North, Seattle, WA 98103 (US). (74) Agent: PARKER, Gary, E.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US). | | (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |

(54) Title: **LOW MOLECULAR WEIGHT THROMBOPOIETIN**

(57) Abstract

Isolated mammalian thrombopoietins are disclosed. The thrombopoietins include polypeptides characterized by an amino acid sequence selected from the group consisting of (a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive; a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive; a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198); a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and allelic variants of (a)-(d). Also disclosed are isolated DNA molecules encoding these polypeptides as well as vectors, cells and methods that can be used for the production of the polypeptides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

Description

LOW MOLECULAR WEIGHT THROMBOPOIETIN

Background of the Invention

Hematopoiesis is the process by which blood cells develop and differentiate from pluripotent stem cells in the bone marrow. This process involves a complex interplay of polypeptide growth factors (cytokines) acting via membrane-bound receptors on their target cells. Cytokine action results in cellular proliferation and differentiation, with response to a particular cytokine often being lineage-specific and/or stage-specific. Development of a single cell type, such as a platelet, from a stem cell may require the coordinated action of a plurality of cytokines acting in the proper sequence.

The known cytokines include the interleukins, such as IL-1, IL-2, IL-3, IL-6, IL-8, etc.; and the colony stimulating factors, such as G-CSF, M-CSF, GM-CSF, erythropoietin (EPO), etc. In general, the interleukins act as mediators of immune and inflammatory responses. The colony stimulating factors stimulate the proliferation of marrow-derived cells, activate mature leukocytes, and otherwise form an integral part of the host's response to inflammatory, infectious, and immunologic challenges.

Various cytokines have been developed as therapeutic agents. For example, erythropoietin, which stimulates the development of erythrocytes, is used in the treatment of anemia arising from renal failure. Several of the colony stimulating factors have been used in conjunction with cancer chemotherapy to speed the recovery of patients' immune systems. Interleukin-2, α -interferon and γ -interferon are used in the treatment of certain cancers. An activity that stimulates megakaryocytopoiesis and thrombocytopoiesis has been identified in body fluids

of thrombocytopenic animals and is referred to in the literature as "thrombopoietin" (recently reviewed by McDonald, Exp. Hematol. 16:201-205, 1988 and McDonald, Am. J. Ped. Hematol. Oncol. 14:8-21, 1992).

5 Recently, several groups have identified and/or cloned a protein that binds to the cellular MPL receptor and stimulates megakaryocytopoiesis and thrombocytopoiesis. See, de Sauvage et al., Nature 369:533-538, 1994; Lok et al., Nature 369:565-568, 1994; 10 Kaushansky et al., Nature 369:568-571, 1994; Wendling et al., Nature 369:571-574, 1994; and Bartley et al., Cell 77:1117-1124, 1994. It has been proposed that this protein be termed thrombopoietin (Kaushansky et al., *ibid.*). Although this protein has been shown to stimulate 15 platelet production *in vivo* (Kaushansky et al., *ibid.*), it appears to be subject to proteolysis and was isolated in heterogeneous or degraded form (Bartley et al., *ibid.*; de Sauvage et al., *ibid.*). Preparations of thrombopoietin reported in the scientific literature are therefore not 20 well characterized as to composition and the relative activities of the various molecular species, although at least some of the proteolytic products are biologically active.

Proteolysis and heterogeneity are significant 25 problems that can impede the development of new pharmaceutical agents. There thus remains a need in the art for reproducible preparations of thrombopoietin. There is a further need for preparations of thrombopoietin having high specific activity. There is a further need 30 for homogeneous and well-characterized preparations of thrombopoietin. There is also a need for methods of making such preparations. The present invention fulfills these needs and provides other, related advantages.

Summary of the Invention

Within one aspect of the present invention there is provided an isolated mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of (a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive; (b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive; (c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198); (d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and (e) allelic variants of (a)-(d). Within one embodiment of the invention, the thrombopoietin is further characterized by a peptide backbone mass of 17,490 to 19,045 amu as determined by mass spectrometry, an absence of N-linked carbohydrate, a presence of O-linked carbohydrate, and being essentially free of thrombopoietin species having a molecular weight greater than 18,885 amu as determined by mass spectrometry. Within another embodiment of the invention, the thrombopoietin is a mixture of polypeptides having different carboxyl termini.

Within a related aspect, the present invention provides a composition of mammalian thrombopoietin consisting essentially of one or more polypeptides having an amino acid sequence consisting of (a) the sequence shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; and (b) allelic variants of (a). Within one embodiment, the composition is further characterized by an absence of N-linked carbohydrate and a presence of O-linked carbohydrate on the one or more polypeptides.

Within another aspect, the present invention provides a composition of mammalian thrombopoietin consisting essentially of one or more polypeptides having an amino acid sequence selected from the group consisting of (a) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198), (b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207), and (c) allelic variants of (a) and (b).

Within another aspect of the present invention there is provided a pharmaceutical composition comprising a thrombopoietin polypeptide as disclosed above in combination with a pharmaceutically acceptable vehicle. Also provided is a method of stimulating platelet production in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of the composition.

Within an additional aspect of the invention, there is provided an isolated DNA molecule encoding a mammalian thrombopoietin as disclosed above. The DNA molecule may be used in the construction of an expression vector. The vector comprises a DNA segment encoding a thrombopoietin as disclosed above operably linked to one or more additional DNA segments that provide for its transcription. Also provided is a cultured eukaryotic cell containing the disclosed expression vector, such as a yeast cell or a cultured mammalian cell. The cultured cell may be used within methods for producing a mammalian thrombopoietin. These methods comprise the steps of culturing a eukaryotic cell containing an expression vector comprising a first DNA segment encoding a mammalian thrombopoietin as disclosed above, wherein the first DNA segment is operably linked to a second DNA segment encoding a secretory peptide and one or more additional DNA segments that provide for transcription of the first

and second DNA segments, and wherein the cell expresses the first and second DNA segments and the thrombopoietin is secreted from the cell and selectively recovered.

These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawings.

Brief Description of the Drawings

Fig. 1 illustrates the effects of a representative thrombopoietin composition of the present invention on platelet levels in mice.

Fig. 2 illustrates the dose-response relationship of platelet levels in mice treated with a representative thrombopoietin composition of the present invention.

Detailed Description of the Invention

Prior to describing the present invention in detail, it may be helpful to define certain terms used herein:

Allelic variant: An alternative form of a gene that arises through mutation, or an altered polypeptide encoded by the mutated gene. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.

cDNA: Complementary DNA, prepared by reverse transcription of a messenger RNA template, or a clone or amplified copy of such a molecule. Complementary DNA can be single-stranded or double-stranded.

Essentially free: At least 95% free of a specified contaminant. When applied to a protein, level of contamination is determined by Edman degradation and amino acid sequencing.

Expression vector: A DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that

C

provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both. The term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.

Gene: A segment of chromosomal DNA that encodes a polypeptide chain. A gene includes one or more regions encoding amino acids, which in some cases are interspersed with non-coding "intervening sequences" ("introns"), together with flanking, non-coding regions which provide for transcription of the coding sequence.

Isolated: When applied to the protein the term "isolated" indicates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the proteins in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When applied to a polynucleotide molecule the term "isolated" indicates that the molecule is removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.

Peptide backbone mass: The molecular mass of a polypeptide or protein in the absence of glycosylation, generally determined by mass spectrometry of deglycosylated protein or calculated from amino acid sequence.

Promoter: The portion of a gene at which RNA polymerase binds and mRNA synthesis is initiated.

Secretory peptide: An amino acid sequence that acts to direct the secretion of a mature polypeptide or protein from a cell. Secretory peptides are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptides from the mature proteins as they pass through the secretory pathway. A DNA sequence encoding a secretory peptide is referred to as a signal sequence, leader sequence, prepro sequence or pre sequence.

Thrombopoietin: Thrombopoietin (TPO) proteins are characterized by their ability to specifically bind to MPL receptor from the same species and to stimulate platelet production *in vivo*. In normal test animals, TPO is able to increase platelet levels by 100% or more within 10 days after beginning daily administration. The term "thrombopoietin polypeptide" encompasses full-length thrombopoietin molecules and biologically active portions thereof, that is fragments of a thrombopoietin that exhibit the qualitative biological activities of the intact molecule (receptor binding and *in vivo* stimulation of platelet production).

The present invention is based in part on the discovery of a class of defined and well-characterized, biologically active thrombopoietin polypeptides having unexpectedly high specific activity, members of which were initially obtained by fractionation of recombinant TPO. TPO compositions of the present invention exhibit an *in vitro* specific activity (units of activity per mole of protein) five to ten times that of conventional TPO preparations that comprise a mixture of glycosylated

polypeptide species ranging in size from about 30 kD to about 70 kD as determined by electrophoresis on SDS-polyacrylamide gels under reducing conditions. The TPO compositions of the present invention have also been found
5 to be fully active *in vivo*.

A recombinant mouse TPO preparation that contained a significant amount of protein with a molecular weight in the 18-22 kD range was fractionated by a combination of affinity chromatography and anion exchange
10 chromatography. This low molecular weight species was analyzed by mass spectrometry and found to have a heterogeneous carboxyl terminus, with the longest and most prevalent form ending at amino acid residue 216 of SEQ ID NO:2, and the shortest form ending at residue 208 of SEQ
15 ID NO:2. The peptide backbone mass of the longest form, taking into consideration two disulfide bonds, was determined to be 18,449 atomic mass units (amu) by mass spectrometry. This low molecular weight TPO contained no N-linked carbohydrate as determined by the absence of a
20 molecular weight shift after digestion with peptide-N-glycosidase F, which is specific for the hydrolysis of β -aspartyl-glycosylamine bonds between asparagine and the innermost N-acetylglucosamine of the glycan moiety; and by mass spectrometry, which indicated that the C-terminus of
25 the polypeptide was upstream of the first N-linked glycosylation site of the full-length TPO molecule. The presence of O-linked carbohydrates on this TPO was determined by a shift in molecular weight after deglycosylation with O-glycosidase. Digestion with
30 sialidase and O-glycosidase in combination with mass spectrometry indicated the presence of at least four different O-linked glycosylation sites with up to eight different glycoforms. The mass range of the carbohydrate structures was from 2260 to 3207. The largest form
35 contained 4 HexNAc, 4 hexose, and 6 NeuAc (sialic acid). The peptide backbone mass of the shortest polypeptide in

this preparation (terminating at residue 208 of SEQ ID NO:2) was 17,492 amu.

The thrombopoietin compositions of the present invention may be a single polypeptide species or a mixture of polypeptides differing at their carboxyl termini but having a common amino terminus. A representative group of such polypeptides derived from mouse TPO includes molecules having a sequence of amino acids as shown in SEQ ID NO:2 from an amino-terminal Ser residue, amino acid residue no. 45, to a carboxyl terminus between residue no. 208 (Ser) and residue no. 216 (Asn), inclusive.

The present invention also provides related TPO polypeptides from species other than mouse. For example, there is provided a group of human TPO polypeptides, the amino acid sequences of which begin at Ser, residue 22 of SEQ ID NO:4 and terminate between residue 185 (Arg) and residue 198 (Arg), inclusive, of SEQ ID NO:4. Of particular interest are the human TPO polypeptides shown in Table 1 (with reference to SEQ ID NO:4), as well as intermediate forms, such as polypeptides having C-termini between Arg (185) and Asn (193).

Table 1

| | |
|----|---------------------|
| | Ser (22)--Arg (185) |
| 25 | Ser (22)--Asn (193) |
| | Ser (22)--Arg (198) |

These human TPO polypeptides are characterized by a peptide backbone mass of approximately 17,593 to 19,045 amu as determined by mass spectrometry. The polypeptide terminating at Asn (193) has a peptide backbone mass of 18,435 amu. These polypeptides are free of N-linked carbohydrate attachment sites, but contain O-linked carbohydrate attachment sites.

Also provided by the present invention is a TPO polypeptide having an amino acid sequence as shown in SEQ ID NO:4 from Ser (22) to Phe (207).

Protein molecular weights are determined by
5 conventional procedures. See, for example, Laemmli, Nature 227:680-685, 1970; McEwan and Larsen, eds., Mass Spectrometry of Biological Materials, Marcel Decker, Inc., New York, 1990; and Carr et al., Analytical Chem. 63:2802-2824, 1991, which are incorporated herein by
10 reference. Proteins can be deglycosylated enzymatically using conventional methods. In a typical procedure, the protein is desalted by high performance liquid chromatography prior to deglycosylation. N-linked carbohydrate is removed using peptide-N-glycosidase F.
15 Sialic acid residues are removed using sialidase (neuraminidase). O-linked carbohydrate is removed using O-glycosidase (endo- α -N-acetylgalactosaminidase) following removal of terminal neuraminic acid moieties with sialidase. Glycosidases and other enzymes are available
20 from commercial suppliers, such as Oxford Glycosystems (Rosedale, NY) and Boehringer Mannheim, Inc. (Indianapolis, IN).

The present invention provides isolated, biologically active, mammalian TPO polypeptides, including
25 human, mouse, rat, porcine, canine, ovine, bovine and equine TPO polypeptides. Of particular interest are primate TPO polypeptides, in particular human TPO polypeptides. Non-human TPO polypeptides of the present invention are, in general, at least 50% identical in amino
30 acid sequence to corresponding portions of the mouse (SEQ ID NO:2) or human (SEQ ID NO:4) sequences disclosed herein. Percent sequence identity of amino acid sequences is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and
35 Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences

11

are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 2 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{[\text{length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences}]} \times 100$$

13

As will be recognized by those skilled in the art, the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4 are merely representative, and allelic variation is expected. Allelic variants are characterized by one or more amino acid substitutions, deletions or additions. In addition, the skilled practitioner will recognize that changes in amino acid sequence can be introduced in TPO molecules through the application of genetic engineering. These engineered changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 3). See, in general Ford et al., Protein Expression and Purification 2: 95-107, 1991, which is incorporated herein by reference.

15

Table 3

Conservative amino acid substitutions

| | | |
|----|--------------|---------------|
| 20 | Basic: | arginine |
| | | lysine |
| | | histidine |
| 25 | Acidic: | glutamic acid |
| | | aspartic acid |
| | Polar: | glutamine |
| 30 | Hydrophobic: | asparagine |
| | | leucine |
| | Aromatic: | isoleucine |
| | | valine |
| | | phenylalanine |
| 35 | Small: | tryptophan |
| | | tyrosine |
| | | glycine |
| | | alanine |
| | | serine |
| | | threonine |
| | | methionine |

14

For the purpose of engineering variant molecules, essential amino acids in TPO may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-1085, 1989). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g. receptor binding, *in vitro* or *in vivo* proliferative activity) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992.

In general, cytokines are predicted to have a four-alpha helix structure, with the first and fourth helices being most important in ligand-receptor interactions and more highly conserved among members of the family. Referring to the human TPO amino acid sequence shown in SEQ ID NO:4, alignment of cytokine sequences suggests that these helices are bounded by amino acid residues 29 and 53, 80 and 99, 108 and 130, and 144 and 168, respectively (boundaries are ± 4 residues). Helix boundaries of the mouse (SEQ ID NO:2) and other non-human TPOs can be determined by alignment with the human sequence. Other important structural aspects of TPO include the cysteine residues at positions 51, 73, 129 and 195 of SEQ ID NO:2 (corresponding to positions 28, 50, 106 and 172 of SEQ ID NO:4).

It is preferred to prepare the TPO polypeptides of the present invention by production in genetically engineered cells or organisms, although isolation from

15

natural sources of TPO (e.g. blood or other biological fluid) is within the scope of the invention. When producing TPO in a genetically engineered host, a DNA segment encoding at least the polypeptide of interest is expressed in the host, and the polypeptide is recovered. The DNA segment may encode additional sequences, for example additional TPO amino acid residues C-terminal to the carboxyl terminus of a TPO polypeptide or a secretory signal sequence. Within one embodiment of the invention, a DNA segment encoding a full-length TPO molecule is expressed, and the resulting TPO is recovered and fractionated to provide a purified preparation of the truncated polypeptide(s). Within another embodiment, a stop codon is introduced (e.g. by site-specific mutagenesis) into the TPO-encoding DNA segment immediately 3' to the terminal codon of the sequence of interest. Within another embodiment, a DNA segment encoding a TPO polypeptide further encodes one or more non-TPO amino acid residues, such as an amino-terminal methionine, a small amino- or carboxyl-terminal extension that provides an antigenic epitope or other binding domain to facilitate purification of the polypeptide, or a heterologous secretory signal sequence.

In general, a DNA segment encoding TPO is operably linked to a transcription promoter and terminator within an expression vector. The vector will commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements

16

are described in the literature and are available through commercial suppliers.

To direct recombinant TPO into the secretory pathway of a host cell, a signal sequence is provided in the expression vector. The signal sequence is joined to the DNA sequence encoding TPO in the correct reading frame. Signal sequences are commonly positioned 5' to the DNA sequence encoding the protein or polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830). The signal sequence may be one normally associated with TPO, or may be from a gene encoding another secreted protein, such as tissue-type plasminogen activator (t-PA). When using a signal sequence encoding a secretory peptide containing internal proteolytic cleavage sites, it is preferred to eliminate such internal sites through mutagenesis.

Yeast cells, particularly cells of the genus *Saccharomyces*, are a preferred host for use in producing recombinant TPO. Methods for transforming yeast cells with exogenous DNA and producing recombinant proteins therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075, which are incorporated herein by reference. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g. leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. A preferred secretory signal sequence for use in yeast is that of the *S. cerevisiae* MF α 1 gene (Brake, *ibid.*;

17

Kurjan et al., U.S. Patent No. 4,546,082). Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092, which are incorporated herein by reference) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986; Cregg, U.S. Patent No. 4,882,279; and Stroman et al., U.S. Patent No. 4,879,231.

Other fungal cells are also suitable as host cells. For example, *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349, which is incorporated herein by reference. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228, which is incorporated herein by reference. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.

Cultured mammalian cells are also preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987), and

18

cationic lipid-mediated transfection (Hawley-Nelson et al., Focus 15:73-79, 1993), which are incorporated herein by reference. The production of recombinant proteins in cultured mammalian cells is disclosed, for example, by 5 Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 10 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and 15 available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include 20 those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978, which are incorporated herein by reference) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been 25 inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is 30 a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as 35 "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of

the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign proteins therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are incorporated herein by reference. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

Transgenic animal technology may also be employed to produce TPO. It is preferred to produce the protein within the mammary glands of a host female mammal. Expression in the mammary gland and subsequent secretion

20

of the protein of interest into the milk overcomes many difficulties encountered in isolating proteins from other sources. Milk is readily collected, available in large quantities, and well characterized biochemically. Furthermore, the major milk proteins are present in milk at high concentrations (from about 1 to 15 g/l).

From a commercial point of view, it is clearly preferable to use as the host a species that has a large milk yield. While smaller animals such as mice and rats can be used (and are preferred at the proof-of-concept stage), it is preferred to use livestock mammals including, but not limited to, pigs, goats, sheep and cattle. Sheep are particularly preferred due to such factors as the previous history of transgenesis in this species, milk yield, cost and the ready availability of equipment for collecting sheep milk. See WIPO Publication WO 88/00239 for a comparison of factors influencing the choice of host species. It is generally desirable to select a breed of host animal that has been bred for dairy use, such as East Friesland sheep, or to introduce dairy stock by breeding of the transgenic line at a later date. In any event, animals of known, good health status should be used.

To obtain expression in the mammary gland, a transcription promoter from a milk protein gene is used. Milk protein genes include those genes encoding caseins (see U.S. Patent No. 5,304,489, incorporated herein by reference), beta-lactoglobulin, α -lactalbumin, and whey acidic protein. The beta-lactoglobulin (BLG) promoter is preferred. In the case of the ovine beta-lactoglobulin gene, a region of at least the proximal 406 bp of 5' flanking sequence of the gene will generally be used, although larger portions of the 5' flanking sequence, up to about 5 kbp, are preferred, such as a -4.25 kbp DNA segment encompassing the 5' flanking promoter and non-coding portion of the beta-lactoglobulin gene. See

2/

Whitelaw et al., Biochem J. 286: 31-39, 1992. Similar fragments of promoter DNA from other species are also suitable.

General procedures for producing transgenic animals are known in the art. See, for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, 1986; Simons et al., Bio/Technology 6: 179-183, 1988; Wall et al., Biol. Reprod. 32: 645-651, 1985; Buhler et al., Bio/Technology 8: 140-143, 1990; Ebert et al., Bio/Technology 9: 835-838, 1991; Krimpenfort et al., Bio/Technology 9: 844-847, 1991; Wall et al., J. Cell. Biochem. 49: 113-120, 1992; U.S. Patents Nos. 4,873,191 and 4,873,316; WIPO publications WO 88/00239, WO 90/05188, WO 92/11757; and GB 87/00458, which are incorporated herein by reference. Techniques for introducing foreign DNA sequences into mammals and their germ cells were originally developed in the mouse. See, e.g., Gordon et al., Proc. Natl. Acad. Sci. USA 77: 7380-7384, 1980; Gordon and Ruddle, Science 214: 1244-1246, 1981; Palmiter and Brinster, Cell 41: 343-345, 1985; Brinster et al., Proc. Natl. Acad. Sci. USA 82: 4438-4442, 1985; and Hogan et al. (ibid.). These techniques were subsequently adapted for use with larger animals, including livestock species (see e.g., WIPO publications WO 88/00239, WO 90/05188, and WO 92/11757; and Simons et al., Bio/Technology 6: 179-183, 1988). To summarize, in the most efficient route used to date in the generation of transgenic mice or livestock, several hundred linear molecules of the DNA of interest are injected into one of the pro-nuclei of a fertilized egg according to techniques which have become standard in the art. Injection of DNA into the cytoplasm of a zygote can also be employed.

Production in transgenic plants may also be employed. Expression may be generalized or directed to a particular organ, such as a tuber. See, Hiatt, Nature 344:469-479, 1990; Edelbaum et al., J. Interferon Res.

22

12:449-453, 1992; Sijmons et al., Bio/Technology 8:217-221, 1990; and European Patent Office Publication EP 255,378.

Within one embodiment of the present invention,
5 low molecular weight TPO is selectively recovered from cell culture media using a combination of ultrafiltration, affinity chromatography and ion exchange chromatography. Additional purification procedures may be employed, such as hydrophobic interaction chromatography. In a typical
10 purification, conditioned medium from cells expressing recombinant TPO, which contains a mixture of TPO species from about 17.5 kD to about 70 kD, is concentrated. Suitable means of concentration include binding to a dye resin and ultrafiltration, the latter being preferred.
15 The degree of concentration will be determined by such factors as initial volume and downstream processing capacity. In general, approximately 20-fold concentration is preferred, with a practical upper limit of about 50-fold in most cases.

20 The concentrated medium is then combined with an immobilized MPL receptor polypeptide comprising at least the ligand-binding domain of the receptor. The ligand binding domain of the mouse MPL receptor is contained within the extracellular portion of the protein (residues
25 27 to 480 of SEQ ID NO: 9), with residues 293-297, 358-361, and 398-419 believed to be of particular importance for ligand binding. In a typical procedure, concentrated medium is adjusted to 0.5 M NaCl and a slightly alkaline pH (preferably about pH 8.0), and the column is
30 equilibrated with a similar buffer. The medium is then applied to the column, and bound TPO polypeptide is eluted with 3 M KSCN, pH 8.0, or 3 M KSCN, 1.0 M NaCl in 0.1 M borate, pH 10.0.

Material eluted from the immobilized receptor is
35 then dialyzed to remove salt, such as in 3-4 changes of 20 mM Tris pH 8.5. The dialyzed sample is then fractionated

on a strong anion exchange medium. Suitable anion exchange media for use in this procedure include polymeric (e.g., agarose, dextran or polystyrene) beads derivatized with quaternary amino groups, used in a fast pressure liquid chromatography format. A preferred anion exchanger is Mono-Q Sepharose (available from Pharmacia Biotech, Piscataway, NJ). Bound TPO is eluted from the anion exchange medium by applying a salt gradient. When using Mono-Q Sepharose, the 18.5 kD species typically elutes at a salt concentration of approximately 0.15 M NaCl.

Within another embodiment of the present invention, a truncated TPO DNA is expressed in an engineered host cell. The resulting TPO polypeptide is secreted into the culture media, the media and cells are separated, and the TPO polypeptide is selectively recovered from the media. The TPO polypeptide can be recovered by a combination of affinity purification and other techniques as disclosed above.

The TPO of the present invention can be used therapeutically wherever it is desirable to increase proliferation of cells in the bone marrow, such as in the treatment of cytopenia, such as that induced by aplastic anemia, myelodysplastic syndromes, chemotherapy or congenital cytopenias. The proteins are also useful for increasing platelet production, such as in the treatment of thrombocytopenia. Thrombocytopenia is associated with a diverse group of diseases and clinical situations that may act alone or in concert to produce the condition. Lowered platelet counts can result from, for example, defects in platelet production, abnormal platelet distribution, dilutional losses due to massive transfusions, or abnormal destruction of platelets. For example, chemotherapeutic drugs used in cancer therapy may suppress development of platelet progenitor cells in the bone marrow, and the resulting thrombocytopenia limits the chemotherapy and may necessitate transfusions. In

24

addition, certain malignancies can impair platelet production and platelet distribution. Radiation therapy used to kill malignant cells also kills platelet progenitor cells. Thrombocytopenia may also arise from various platelet autoimmune disorders induced by drugs, neonatal alloimmunity or platelet transfusion alloimmunity. The proteins of the present invention can reduce or eliminate the need for transfusions, thereby reducing the incidence of platelet alloimmunity.

10 Abnormal destruction of platelets can result from: (1) increased platelet consumption in vascular grafts or traumatized tissue; or (2) immune mechanisms associated with, for example, drug-induced thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), autoimmune

15 diseases, hematologic disorders such as leukemia and lymphoma, or metastatic cancers involving bone marrow. Other indications for the proteins of the present invention include aplastic anemia and drug-induced marrow suppression resulting from, for example, chemotherapy or

20 treatment of HIV infection with AZT.

Thrombocytopenia is manifested as increased bleeding, such as mucosal bleedings from the nasal-oral area or the gastrointestinal tract, as well as oozing from wounds, ulcers or injection sites.

25 For pharmaceutical use, TPO is formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general,

30 pharmaceutical formulations will include TPO in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents,

35 albumin to prevent protein loss on vial surfaces, etc. In addition, TPO can be combined with other cytokines,

25

particularly early-acting cytokines such as stem cell factor, IL-3, IL-6, IL-11 or GM-CSF. When utilizing such a combination therapy, the cytokines may be combined in a single formulation or may be administered in separate formulations. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference. Therapeutic doses of the TPO of the present invention will generally be in the range of 0.1 to 100 $\mu\text{g/kg}$ of patient weight per day, preferably 0.5-50 $\mu\text{g/kg}$ per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. In certain cases, such as when treating patients showing increased sensitivity or requiring prolonged treatment, doses in the range of 0.1-20 $\mu\text{g/kg}$ per day will be indicated. Determination of dose is within the level of ordinary skill in the art. TPO will commonly be administered over a period of up to 28 days following chemotherapy or bone-marrow transplant or until a platelet count of $>20,000/\text{mm}^3$, preferably $>50,000/\text{mm}^3$, is achieved. More commonly, TPO will be administered over one week or less, often over a period of one to three days. In general, a therapeutically effective amount of TPO is an amount sufficient to produce a clinically significant increase in the proliferation and/or differentiation of lymphoid or myeloid progenitor cells, which will be manifested as an increase in circulating levels of mature cells (e.g. platelets or neutrophils). Treatment of platelet disorders will thus be continued until a platelet count of at least $20,000/\text{mm}^3$, preferably $50,000/\text{mm}^3$, is reached. TPO can also be administered in combination with other cytokines such as IL-3, -6 and -11; stem cell factor; erythropoietin; G-CSF and GM-CSF. Within regimens of

26

combination therapy, daily doses of other cytokines will in general be: EPO, ≤ 150 U/kg; GM-CSF, 5-15 $\mu\text{g/kg}$; IL-3, 1-5 $\mu\text{g/kg}$; and G-CSF, 1-25 $\mu\text{g/kg}$. Combination therapy with EPO, for example, is indicated in anemic patients with low
5 EPO levels, wherein EPO is administered in an amount sufficient to increase erythropoiesis. Increased erythropoiesis is manifested as a subsequent increase in hematocrit.

TPO is also a valuable tool for the *in vitro*
10 study of the differentiation and development of hematopoietic cells, such as for elucidating the mechanisms of cell differentiation and for determining the lineages of mature cells, and may also find utility as a proliferative agent in cell culture.

15 TPO can also be used *ex vivo*, such as in autologous marrow culture. Briefly, bone marrow is removed from a patient prior to chemotherapy and treated with TPO, optionally in combination with one or more other cytokines. The treated marrow is then returned to the
20 patient after chemotherapy to speed the recovery of the marrow. In addition, TPO can be used for the *ex vivo* expansion of marrow or peripheral blood progenitor (PBPC) cells. Prior to chemotherapy treatment, marrow can be stimulated with stem cell factor (SCF) or G-CSF to release
25 early progenitor cells into peripheral circulation. These progenitors can be collected and concentrated from peripheral blood and then treated in culture with TPO, optionally in combination with one or more other cytokines, including but not limited to SCF, G-CSF, IL-3,
30 GM-CSF, IL-6 or IL-11, to differentiate and proliferate into high-density megakaryocyte cultures, which can then be returned to the patient following high-dose chemotherapy.

The invention is further illustrated by the
35 following non-limiting examples.

ExamplesExample 1

Plasmid pZGmpl-1081 (deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on February 14, 1994 as an *E. coli* DH5 α transformant and assigned accession number 69566) was digested with Eco RI and Not I, and the TPO DNA segment was recovered. This DNA was inserted into Eco RI-digested, alkaline phosphatase-treated plasmid Zem229R with a Not I/Eco RI linker. (Zem229R was deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on September 23, 1993 as an *E. coli* HB101 transformant and assigned accession number 69447.) The resulting plasmid, designated mpl.229R, was transfected into BHK 570 cells (ATCC CRL 10314). The transfectants were grown in 10-layer cell factories (Nunc, Inc.; obtained from VWR Scientific, Seattle, WA) in serum-free medium and selected 1 μ M methotrexate. Sixteen liters of conditioned culture medium was collected.

TPO was purified from the conditioned medium by affinity chromatography on immobilized MPL receptor. Eighty mg of purified mouse MPL receptor extracellular domain (see Example 7) was immobilized on 8 ml of Affi-Prep 10 acrylic polymer support (Bio-Rad Laboratories, Inc.) using procedures specified by the manufacturer. The receptor-support matrix was packed into an 8 ml column.

The conditioned cell culture media, which contained a prominent TPO band of approximately $M_r=18.5$ kD, was concentrated 29-fold on a 10 kD cut off hollow fiber membrane (A/G Technology Corp., Needham, MA). The concentrated media was cycled over the affinity column for several hours or overnight in the cold. After washing the column to baseline absorbance (at 280 nm) with 20 mM Tris pH 8.5, the column was eluted with 3 M KSCN (Fluka

28

Chemical Corp., Ronkonkoma, NY). Eluate fractions were pooled and dialyzed against 20 mM Tris pH 8.5.

The dialyzed protein was applied to a Mono-Q Sepharose column (Pharmacia Biotech, Piscataway, NJ) at pH 8.5. Bound TPO was eluted from the column with a NaCl gradient (0 to 0.5 M). Peak fractions were identified by monitoring absorbance at 220 nm and "western" blotting.

Units of TPO activity were determined by assaying mitogenic activity on a TPO-dependent cell line. A BHK 570 cell line transfected with the mouse TPO expression vector pZGmpl-1081 was grown in serum-free medium. Conditioned culture medium was collected, and an asymptotic mitogenic activity curve was generated using this standard solution. The target cells were BaF3/MPLR1.1 cells (IL-3-dependent cells expressing a stably transfected Type I mouse MPL receptor; deposited September 28, 1994 under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD and assigned accession number CRL 11723). The point of 1/2 maximal activity (average of 16 curves) was assigned the value of 50 U/ml. The original standard solution was calculated to contain 26,600 U/ml mouse TPO.

For test samples, a culture supernatant or purified protein preparation was diluted in RPMI 1640 medium supplemented with 57 μ M 2-mercaptoethanol, 2 mM L-glutamine, 1 mM sodium pyruvate, PSN antibiotic mixture, 10 mM HEPES and 10% heat inactivated fetal bovine serum, generally using 8-24 dilutions. Briefly, 100 μ l of diluted test sample or standard sample and 100 μ l BaF3 cells (final cell number added about 10,000 cells/well) were combined in wells of a 96 well plate. Internal standards included eight 2-fold dilutions of 100 U/ml mouse TPO for mouse TPO assays, or eight 2-fold dilutions of 150 U/ml mouse TPO for human TPO assays. To each well was added 2 μ l 3 H-

29

thymidine (1 $\mu\text{Ci}/\mu\text{l}$; Amersham), and the plates were incubated overnight at 37°C.

The contents of each well of each plate were transferred to a filter/plate using a Packard apparatus.

5 The filters were washed 8 times with water, and the filters were dried and counted. Units of TPO activity in each sample well were determined by comparison to the standard curve.

The activity of the protein was determined to be 10 14×10^6 U/ml. Protein concentration was 30 $\mu\text{g}/\text{ml}$.

Example 2

Thrombopoietin polypeptide from the preparation disclosed in Example 1 ran at approximately 20 kDa on a 15 non-reducing SDS PAGE gel (less than the 35,594.9 amu predicted on the basis of the amino acid sequence) and was active *in vitro*. Edman degradation indicated that the N-terminus was intact. These data demonstrate that the TPO had been proteolytically processed at the C-terminus.

20 To determine the C-terminal processing site of the ca. Mr=18.5 kD mouse TPO, the polypeptide was further analyzed by enzymatic deglycosylation and mass spectrometry. A sequential deglycosylation experiment was set up to determine if N or/and O-glycosylation were 25 present. Results of this experiment would tell if the processing site was before or after the first N-linked glycosylation site. In addition, deglycosylation of all N and O-linked sugars was necessary to carry out mass spectrometry for determination of the C-terminus.

30 A sample of the polypeptide was desalted by reverse phase HPLC. 222.6 μg of sample was desalted on a 2.1 mm X 150 mm PLRP-S 4000 column (Polymer Laboratories, Inc., Amherst, MA) in two separate runs of 111 μg each using conditions shown in Table 4.

30

Table 4

HPLC: Michrom Bioresource Ultrafast
 Michroprotein Analyzer.

5 Solvent A : 2% CH₃CN / 0.01% TFA/ H₂O.
 Solvent B: 10% H₂O / 90% CH₃CN / 0.09% TFA.

| | Gradient: <u>Time(minutes)</u> <u>% Solvent B</u> | |
|----|---|----|
| | | |
| | 0 | 10 |
| | 20 | 98 |
| 10 | 22 | 98 |
| | 25 | 10 |

Wavelength: 215 nm; Flow 0.5 ml/minute.

The eluates were collected manually. The final
 15 volume of the eluate was 1.57 ml. Subvials of 15 X 100 µl
 (approximately 14.1 µg per 100 µl vial) and 1 X 70 µl were
 concentrated in a vacuum concentrator (Savant Speed Vac)
 and stored at -20°C.

Sequential digestion of the sample was performed
 20 with peptide-N-glycosidase F (PNGase F), sialidase, and O-
 glycosidase to determine if N- or/and O-linked
 glycosylation were present. Deglycosylation was carried
 out in three steps.

To remove N-linked sugars, two aliquots of 28.2
 25 µg of desalted polypeptide were each reconstituted in 100
 µl of PNGase F reaction buffer (20 mM sodium phosphate pH
 7.5, 50 mM EDTA, and 0.02% sodium azide). Five µl of
 PNGase F was added to one sample, and the remaining sample
 was used as a control for the reaction. Both samples were
 30 incubated at 37°C for 18 hours. PNGase F (purchased from
 Oxford Glycosystems, Rosedale, NY at a concentration of
 150-200 U/ml) cleaves the beta aspartyl-glycosylamine bond
 between asparagine and the innermost N-acetylglucosamine
 of the glycan. As a positive control for this reaction, 1
 35 ug of a mouse TPO known to contain N-linked sugars and
 migrate at approximately 70 kDa on a SDS PAGE reducing gel

31
was used. After 18 hours, 2 X 5 μ l of the PNGase F digested material was removed and stored at -20°C for gel analysis.

5 μ l of sialidase (purchased from Oxford Glycosystems at a concentration of 5 mU per μ l) was added to the remainder of the PNGase F-digested material, and the mixture and incubated for two hours at 37°C . After the incubation was complete, two 5 μ l aliquots of the digest were stored at -20°C for gel analysis. Sialidase is an
10 exoglycosidase that specifically cleaves the terminal neuraminic acid. This reaction is required prior to cleaving O-linked sugars in mammalian proteins.

5 μ l (1.5 mU) of O-glycosidase (Oxford Glycosystems; 300 mU/ml) was added to the remainder of the
15 digested sample and then incubated for 18 hours at 37°C . O-glycosidase is specific for liberating Gal β 1-3GalNAc from serine or threonine.

The sequential digestion was then analyzed by silver stain and western blot analysis. Samples were
20 electrophoresed on 4-20% reducing SDS PAGE gels, 1.0 mm in thickness (Novex, San Diego, CA). Gels were stained with Novex Silver Express stain. For western blot analysis, rat anti-mouse TPO antisera (1:1000 dilution) was used. The western blot and silver stain results showed that
25 there were no N-linked glycosylation sites on the mouse TPO polypeptide, indicating that the cleavage site of this form must be N-terminal to asparagine-220 of SEQ ID NO:2. The positive control showed a shift from 70 kDa to 45 kDa. After digestion with O-glycanase, there was a shift in
30 molecular weight of the truncated polypeptide, indicating the presence of O-glycosylation.

Mass spectral analysis was performed on 28 μ g of the polypeptide in three samples: with O-linked sugars present; after removal of sialic acid; and after
35 sequential deglycosylation. The samples were all desalted prior to analysis and reconstituted in 100 μ l of a 1:1

32

ratio of 0.1% formic acid/H₂O and 0.08% formic acid in ethanol/propanol (5:2). Electrospray mass spectra were recorded on a Sciex (Thornhill, Ontario) API III triple quadrupole mass spectrometer fitted with an articulated
5 ionspray plenum and an atmospheric pressure ionization source. The mass spectrometer was tuned and calibrated using a mixture of polypropylene glycols (PPG) 425, 1,000, and 2,000 (3.3×10^{-5} M, 1×10^{-4} M, and 2×10^{-4} M, respectively), in 50/50/0.1 H₂O/methanol/formic acid
10 (v/v/v), 1 mM NH₄OAc. Normal scan ESMS were recorded at instrument conditions sufficient to resolve isomers of the PPG/NH₄⁺ doubly charged ion at m/z 520 (85% valley definition). Each sample was infused at 5 μ l per minute with up to 81 scans averaged. The mass spectrometer was
15 scanned over a range of m/z 1200-2400, with a dwell time of 2 mSec and a step size of 0.1 amu. The orifice potential was set at 150 V.

Reconstructed ion chromatogram mass spectra of the fully deglycosylated sample showed a heterogeneous C-
20 terminus, starting at serine residue 208 and ending at asparagine residue 216. The masses found take into consideration that 4 amu are subtracted from the predicted mass due to disulfide bond formation and 1 amu is subtracted from the final MH⁺ mass shown in the MacBiospec
25 sequence analysis.

The information obtained from mass spectral analysis revealed that each of the O-linked carbohydrate chains on the sample had one of the following compositions, with the addition of up to six sialic acids
30 on the N-terminal sugar of each chain: 5 HexNAc, 5 Hexose; 4 HexNAc, 4 Hexose; 3 HexNAc, 3 Hexose.

Example 3

Recombinant TPO, prepared as disclosed in
35 Example 1 (TPO 711), was tested for thrombopoietic activity in mice.

33

Female Balb/c mice (obtained from Jackson Laboratories, Bar Harbor, ME) were divided into six groups (five treatment groups and one control group) of four mice each. On day -7, 50 μ l of blood was collected by retro-orbital bleed in a Microtainer tube (Becton Dickinson, Rutherford, NJ), and complete blood counts were performed.

Recombinant TPO was administered by intraperitoneal injection on days 1 through 10. Group I received vehicle (prepared by combining 2 ml 1 M Tris pH 8.0 stock, 98 ml USP water for injection, 250 mg rabbit serum albumin and 0.93 g NaCl) only. Group II received 20 kU/day recombinant TPO from cells expressing a full-length mouse TPO cDNA (designated TPO 525). This primary TPO species in this preparation had apparent molecular weights of approximately 30 and 70 kD. Groups III-VI received 5, 10, 20 or 50 kU/day, respectively, of recombinant TPO 711. All mice were bled and blood counts were performed on days 3, 7, 10 and 14. Body weight was monitored on days -7 or -5, 3, 7, 10 and 14. On day 14, mice were anesthetized by injection with a ketamine/Rompun mixture or by inhalation of metaflane. Blood was collected, and the animals were sacrificed in a CO₂ chamber or by cervical dislocation.

Results of the study are presented in Table 5. Data for days 3, 7, 10 and 14 are shown as percent of basal (day 0) platelet counts. TPO 711 at 50 kU/day increased platelet levels 2.7 fold on day 10, similar to the peak response seen with TPO 525 on day 7. These results indicate that the truncated TPO 711 is at least as active as TPO 525. A dose-response relationship was seen for TPO 711 on days 10 and 14.

34
Table 5

| | | Platelet Count, % of Basal (mean \pm SD) | | | |
|---|--------------|--|--------------|---------------|---------------|
| | <u>Group</u> | <u>Day 3</u> | <u>Day 5</u> | <u>Day 10</u> | <u>Day 14</u> |
| 5 | I | 97 \pm 14 | 113 \pm 15 | 108 \pm 16 | 117 \pm 16 |
| | II | 100 \pm 5 | 290 \pm 59 | 230 \pm 23 | 249 \pm 83 |
| | III | 93 \pm 9 | 166 \pm 23 | 126 \pm 13 | 129 \pm 25 |
| | IV | 95 \pm 7 | 147 \pm 24 | 173 \pm 21 | 164 \pm 22 |
| | V | 90 \pm 22 | 164 \pm 27 | 176 \pm 42 | 194 \pm 31 |
| | VI | 141 \pm 38 | 173 \pm 50 | 271 \pm 46 | 214 \pm 43 |

10

Example 4

A second series of experiments was conducted to compare the effects of TPO 711 administered by once daily injection and twice daily injection.

15 Three groups of female Balb/c mice (Jackson Laboratories) were used. Group I (control; n=3) received twice daily injections of vehicle (prepared by combining 2 ml 1 M Tris pH 8.0 stock, 98 ml USP water for injection, 250 mg rabbit serum albumin and 0.93 g NaCl) alone. Group
20 II (n=4) received daily intraperitoneal injections of 50 kU TPO. Group III received twice daily i.p. injections of 25 kU TPO (50 kU/day).

On day -7, 50 μ l of blood was collected from each animal by orbital sinus bleeding, and blood counts were
25 determined. On day 0, injections were begun. Injections were continued through day 10. The animals were bled again on days 3 and 7 for blood counts. On day 10 the animals were sacrificed in a CO₂ chamber, and platelet counts were determined.

30 Results of this study (shown in Fig. 1) indicated that treatment with 25 kU TPO 711 twice daily increases platelet counts by more than 300% by day 7. Twice-daily administration produced higher platelet counts than the same dose given in a single injection.

35

35

Example 5

Experiments were conducted to compare the effects of TPO 711 administered twice daily vs. once daily and to compare intraperitoneal and subcutaneous routes of injection. In addition, a dose-response curve was established.

Female Balb/c mice weighing about eighteen grams each (Jackson Laboratories, Bar Harbor, ME) were divided into seven groups as shown in Table 6. Groups I-V received the indicated dose (determined as disclosed in Example 1) administered as two equal intraperitoneal injections per day. Group VI received a single, daily i.p. injection. Group VII received a single, daily subcutaneous injection.

15

Table 6

| | <u>Group</u> | <u>Treatment</u> | <u>n</u> |
|----|--------------|------------------|----------|
| | I | vehicle control | 4 |
| | II | 20 kU TPO/day | 4 |
| 20 | III | 50 kU TPO/day | 4 |
| | IV | 100 kU TPO/day | 4 |
| | V | 200 kU TPO/day | 4 |
| | VI | 100 kU TPO/day | 4 |
| | VII | 100 kU TPO/day | 4 |

25

On day -7, all animals were bled, and complete blood counts (CBC), differential blood counts, and reticulocyte counts were determined. Treatment began on day 0 and continued through day 10. On day 3, blood was collected from each animal for determination of CBC, differentials and reticulocytes. On day 7, blood was collected from each animal, CBC and differentials were determined, and the animals were weighed. On day 10, each animal was bled, CBC were determined, body weight was measured, and the animals were sacrificed with CO₂.

35

36

As shown in Fig. 2, treatment with TPO 711 caused a dose-dependent increase in platelet counts over the 11 day duration of the study.

As shown in Table 7, twice daily administration resulted in a higher platelet response than did once daily administration. Subcutaneous injection once a day resulted in a higher platelet response than did i.p. injection.

10

Table 7

| | | Platelet Count (Day 10) |
|----|--------------|---------------------------------|
| | | <u>% of Basal (mean +/- SD)</u> |
| 15 | <u>Group</u> | |
| | I | 100.7 ± 22.6 |
| | II | 206.9 ± 32.3 |
| | III | 292.6 ± 70.8 |
| | IV | 301.2 ± 73.7 |
| | V | 351.3 ± 36.9 |
| | VI | 123.4 ± 27.2 |
| 20 | VII | 193.3 ± 14.6 |

20

Example 6

A vector was constructed for expression of a TPO polypeptide ending at amino acid residue 193 of SEQ ID NO:4. The human TPO DNA sequence was mutagenized by PCR to introduce a stop codon and an EcoRI site following the codon for amino acid 193. Ten ng of template DNA was combined with 5 µl of 2 mM dNTPs, 5 µl 10x Taq buffer (Boehringer Mannheim, Indianapolis, IN), 0.2 µl Taq DNA polymerase (Boehringer Mannheim), 40 pmole of each primer ZC8045 (SEQ ID NO:5) and ZC7878 (SEQ ID NO:6), and H₂O to 50 µl. The mixture was incubated for 30 cycles of 95°C, 1 minute; 50°C, 2 minutes; and 72°C, 1 minute, with a final ten minute incubation at 72°C. DNA was isolated from the reaction mixture and digested with PstI and Eco RI, and a 204 bp fragment encoding amino acid residues 127-193 of

37

SEQ ID NO:4 was recovered by electrophoresis and centrifugal extraction from a gel slice.

To construct the expression vector, the isolated PCR product was ligated with an EcoRI-PstI fragment encoding a modified human t-PA leader and amino acid residues 22-126 of SEQ ID NO:4, and Zem229R (deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on September 28, 1993 as an *E. coli* HB101 transformant and assigned Accession Number 69447) that had been digested with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* DH10b™ cells (GIBCO BRL, Gaithersburg, MD). The plasmid was designated TPO202.229R.

BHK cells were transfected with TPO202.229R using a 3:1 liposome formulation of 2,3-dioleoyloxy-N-[2(sperminecarboxyamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate and dioleoylphosphatidylethanolamine in water (Lipofectamine™ reagent, GIBCO). Transfectants were selected in 500 nM methotrexate (MTX). Pooled cells produced 13,110 U/ml TPO. After amplification in 5 μM MTX, pooled cells produced 20,850 U/ml/day TPO.

The 646 bp EcoRI insert was removed from TPO202.229R and ligated to the vector pDX (disclosed in U.S. Patent No. 4,959,318) that had been linearized by digestion with EcoRI and treated with alkaline phosphatase. The resulting vector, designated TPO202.pDX, was cotransfected into BHK 570 cells with Zem229R. Cells amplified in 500 nM MTX produced 17,000 U/ml/day TPO.

Example 7

Spleens from C57BL/KsJ-db/db mice were removed and immediately placed in liquid nitrogen. Total RNA was prepared from spleen tissue using guanidine isothiocyanate (Chirgwin et al., Biochemistry 18: 52-94, 1979) followed

39

by a CsCl centrifugation step. Spleen poly(A)⁺ RNA was isolated using oligo d(T) cellulose chromatography (Aviv and Leder, Proc. Natl. Acad. Sci. U.S.A. 69: 1408-1412, 1972).

5 Seven and a half μ l of poly d(T)-selected poly(A)⁺ mouse spleen RNA at a concentration of 1.7 μ g/ μ l was mixed with 3 μ l of 20 pmole/ μ l first strand primer ZC6091 (SEQ ID NO:7) containing a Not I restriction site. The mixture was heated at 65° C for 4 minutes and cooled
10 by chilling on ice. First strand cDNA synthesis was initiated by the addition of 8 μ l of 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂ (5x SUPERSCRIPT™ buffer; GIBCO BRL), 4 μ l of 100 mM dithiothreitol and 3 μ l of a deoxynucleotide triphosphate solution containing 10 mM
15 each of dATP, dGTP, dTTP and 5-methyl-dCTP (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ) to the RNA-primer mixture. The reaction mixture was incubated at 45° C for 4 minutes followed by the addition of 10 μ l of 200 U/ μ l RNase H⁻ reverse transcriptase (GIBCO BRL, Gaithersburg,
20 MD). The efficiency of the first strand synthesis was analyzed in a parallel reaction by the addition of 10 μ Ci of ³²P- α dCTP to a 10 μ l aliquot of the reaction mixture to label the reaction for analysis. The reactions were incubated at 45° C for 1 hour followed by an incubation at
25 50° C for 15 minutes. Unincorporated ³²P- α dCTP in the labeled reaction was removed by chromatography on a 400 pore size gel filtration column (CHROMA SPIN + TE-400™; Clontech Laboratories Inc., Palo Alto, CA). Unincorporated nucleotides in the unlabeled first strand
30 reaction were removed by twice precipitating the cDNA in the presence of 8 μ g of glycogen carrier, 2.5 M ammonium acetate and 2.5 volume ethanol. The unlabeled cDNA was resuspended in 50 μ l water for use in second strand synthesis. The length of the labeled first strand cDNA
35 was determined by agarose gel electrophoresis.

39

Second strand synthesis was performed on first strand cDNA under conditions that promoted first strand priming of second strand synthesis resulting in DNA hairpin formation. The reaction mixture was assembled at room temperature and consisted of 50 μ l of the unlabeled first strand cDNA, 16.5 μ l water, 20 μ l of 5x polymerase I buffer (100 mM Tris: HCl, pH 7.4, 500 mM KCl, 25 mM MgCl₂, 50 mM (NH₄)₂SO₄), 1 μ l of 100 mM dithiothreitol, 2 μ l of a solution containing 10 mM of each deoxynucleotide triphosphate, 3 μ l of 5 mM β -NAD, 15 μ l of 3 U/ μ l *E. coli* DNA ligase (New England Biolabs Inc., Beverly, MA) and 5 μ l of 10 U/ μ l *E. coli* DNA polymerase I (Amersham Corp., Arlington Heights, IL). The reaction was incubated at room temperature for 5 minutes followed by the addition of 1.5 μ l of 2 U/ μ l RNase H (GIBCO BRL). A parallel reaction in which a 10 μ l aliquot of the second strand synthesis mixture was labeled by the addition of 10 μ Ci ³²P- α dCTP was used to monitor the efficiency of second strand synthesis. The reactions were incubated at 15° C for two hours followed by a 15 minute incubation at room temperature. Unincorporated ³²P- α dCTP in the labeled reaction was removed by chromatography through a 400 pore size gel filtration column (Clontech Laboratories, Inc.) before analysis by agarose gel electrophoresis. The unlabeled reaction was terminated by two extractions with phenol/chloroform and a chloroform extraction followed by ethanol precipitation in the presence of 2.5 M ammonium acetate.

The single-stranded DNA of the hairpin structure was cleaved using mung bean nuclease. The reaction mixture contained 100 μ l of second strand cDNA, 20 μ l of 10x mung bean nuclease buffer (Stratagene Cloning Systems, La Jolla, CA), 16 μ l of 100 mM dithiothreitol, 51.5 μ l of water and 12.5 μ l of a 1:10 dilution of mung bean nuclease (Promega Corp.; final concentration 10.5 U/ μ l) in mung bean nuclease dilution buffer. The reaction was incubated at

40

37° C for 15 minutes. The reaction was terminated by the addition of 20 μ l of 1 M Tris-HCl, pH 8.0 followed by sequential phenol/chloroform and chloroform extractions as described above. Following the extractions, the DNA was
5 precipitated in ethanol and resuspended in water.

The resuspended cDNA was blunt-ended with T4 DNA polymerase. The cDNA, which was resuspended in 190 μ l of water, was mixed with 50 μ l 5x T4 DNA polymerase buffer (250 mM Tris-HCl, pH 8.0, 250 mM KCl, 25 mM MgCl₂), 3 μ l
10 0.1 M dithiothreitol, 3 μ l of a solution containing 10 mM of each deoxynucleotide triphosphate and 4 μ l of 1 U/ μ l T4 DNA polymerase (Boehringer Mannheim Corp., Indianapolis, IN). After an incubation of 1 hour at 10° C, the reaction was terminated by the addition of 10 μ l of 0.5 M EDTA
15 followed by serial phenol/chloroform and chloroform extractions as described above. The DNA was chromatographed through a 400 pore size gel filtration column (Clontech Laboratories Inc.) to remove trace levels of protein and to remove short cDNAs less than -400 bp in
20 length. The DNA was ethanol precipitated in the presence of 12 μ g glycogen carrier and 2.5 M ammonium acetate and was resuspended in 10 μ l of water. Based on the incorporation of ³²P- α dCTP, the yield of cDNA was estimated to be -2 μ g from a starting mRNA template of 12.5 μ g.

25 *Eco* RI adapters were ligated onto the 5' ends of the cDNA to enable cloning into a lambda phage vector. A 10 μ l aliquot of cDNA (-2 μ g) and 10 μ l of 65 pmole/ μ l of *Eco* RI adapter (Pharmacia LKB Biotechnology Inc.) were mixed with 2.5 μ l 10x ligase buffer (Promega Corp.), 1 μ l
30 of 10 mM ATP and 2 μ l of 15 U/ μ l T4 DNA ligase (Promega Corp.). The reaction was incubated overnight (-18 hours) at a temperature gradient of 0° C to 18° C. The reaction was further incubated overnight at 12° C. The reaction was terminated by the addition of 75 μ l of water and 10 μ l
35 of 3 M Na acetate, followed by incubation at 65° C for 30 minutes. After incubation, the cDNA was extracted with

4/

phenol/chloroform and chloroform as described above and precipitated in the presence of 2.5 M ammonium acetate and 1.2 volume of isopropanol. Following centrifugation, the cDNA pellet was washed with 70% ethanol, air dried and
5 resuspended in 89 μ l water.

To facilitate the directional cloning of the cDNA into a lambda phage vector, the cDNA was digested with Not I, resulting in a cDNA having 5' Eco RI and 3' Not I cohesive ends. The Not I restriction site at the 3' end of the cDNA had been previously introduced through
10 primer ZG6091 (SEQ ID NO:7). Restriction enzyme digestion was carried out in a reaction mixture containing 89 μ l of cDNA described above, 10 μ l of 6 mM Tris-HCl, 6 mM MgCl₂, 150 mM NaCl, 1 mM DTT (10x D buffer; Promega Corp.,
15 Madison, WI) and 1 μ l of 12 U/ μ l Not I (Promega Corp.). Digestion was carried out at 37° C for 1 hour. The reaction was terminated by serial phenol/chloroform and chloroform extractions. The cDNA was ethanol
precipitated, washed with 70% ethanol, air dried and
20 resuspended in 20 μ l of 1x gel loading buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5% glycerol and 0.125% bromphenol blue).

The resuspended cDNA was heated to 65°C for 5 minutes, cooled on ice and electrophoresed on a 0.8% low
25 melt agarose gel (SEA PLAQUE GTG™ low melt agarose; FMC Corp.). Unincorporated adapters and cDNA below 1.6 kb in length were excised from the gel. The electrodes were reversed, and the cDNA was electrophoresed until concentrated near the lane origin. The area of the gel
30 containing the concentrated cDNA was excised and placed in a microfuge tube, and the approximate volume of the gel slice was determined. An aliquot of water (300 μ l) approximately three times the volume of the gel slice was added to the tube, and the agarose was melted by heating
35 to 65° C for 15 minutes. Following equilibration of the sample to 42° C, 10 μ l of 1 U/ μ l β -agarase I (New England

42

Biolabs, Inc.) was added, and the mixture was incubated for 90 minutes to digest the agarose. After incubation, 40 μ l of 3 M Na acetate was added to the sample, and the mixture was incubated on ice for 15 minutes. The sample
5 was centrifuged at 14,000 x g for 15 minutes at room temperature to remove undigested agarose. The cDNA in the supernatant was ethanol precipitated, washed in 70% ethanol, air-dried and resuspended in 37 μ l of water for the kinase reaction to phosphorylate the ligated Eco RI
10 adapters.

To the 37 μ l cDNA solution described above was added 10 μ l 10x ligase buffer (Stratagene Cloning Systems), and the mixture was heated to 65° C for 5 minutes. The mixture was cooled on ice, and 5 μ l 10 mM ATP and 3 μ l of
15 10 U/ μ l T4 polynucleotide kinase (Stratagene Cloning Systems) were added. The reaction was incubated at 37°C for 45 minutes and was terminated by heating to 65° C for 10 minutes followed by serial extractions with phenol/chloroform and chloroform. The phosphorylated cDNA
20 was ethanol precipitated in the presence of 2.5 M ammonium acetate, washed with 70% ethanol, air dried and resuspended in 12.5 μ l water. The concentration of the phosphorylated cDNA was estimated to be ~40 fmole/ μ l.

The resulting cDNA was cloned into the lambda
25 phage vector λ ExCell™ (Pharmacia LKB Biotechnology Inc.), purchased predigested with Eco RI and Not I and dephosphorylated. Ligation of cDNA to vector was carried out in a reaction containing 2 μ l of 20 fmole/ μ l prepared λ ExCell™ phage arms, 4 μ l of water, 1 μ l 10x ligase buffer
30 (Promega Corp.), 2 μ l of 40 fmole/ μ l cDNA and 1 μ l of 15 U/ μ l T4 DNA ligase (Promega Corp.). Ligation was carried out at 4° C for 48 hours. Approximately 50% of the ligation mixture was packaged into phage using GIGAPACK® II Gold packaging extract (Stratagene Cloning Systems)
35 according to the directions of the vendor. The resulting cDNA library contained over 1.5×10^7 independent

43

recombinants with background levels of insertless phage of less than 1.5%.

A ^{32}P -labeled human MPL-K receptor cDNA probe was used to isolate mouse MPL receptor cDNA from the mouse spleen cDNA phage library. The cDNA library was plated on SURE® strain of *E. coli* cells (Stratagene Cloning Systems) at a density of 40,000 to 50,000 PFU/150 mm diameter plate. Phage plaques from thirty-three plates were transferred onto nylon membranes (Hybond N™; Amersham Corp., Arlington Heights, IL) and processed according to the directions of the manufacturer. The processed filters were baked for 2 hours at 80° C in a vacuum oven followed by several washes at 70° C in wash buffer (0.25 x SSC, 0.25% SDS, 1 mM EDTA) and prehybridized overnight at 65° C in hybridization solution (5x SSC, 5x Denhardt's solution, 0.1% SDS, 1 mM EDTA and 100 µg/ml heat denatured salmon sperm DNA) in a hybridization oven (model HB-2; Techne Inc., Princeton, NJ). Following prehybridization, the hybridization solution was discarded and replaced with fresh hybridization solution containing approximately 2×10^6 cpm/ml of ^{32}P -labeled human MPL-K cDNA prepared by the use of a commercially available labeling kit (MEGAPRIME™ kit; Amersham Corp., Arlington Heights, IL). The probe was denatured at 98° C for 5 minutes before being added to the hybridization solution. Hybridization was at 65° C overnight. The filters were washed at 55° C in wash buffer (0.25 x SSC, 0.25% SDS, 1 mM EDTA) and were autoradiographed with intensifying screens for 4 days at -70° C on XAR-5 film (Eastman Kodak Co., Rochester, NY). Employing the autoradiograph as template, agar plugs were recovered from regions of the plates corresponding to primary signals and were soaked in SM (0.1 M NaCl; 50 mM Tris-HCl, pH 7.5, 0.02% gelatin) to elute phage for plaque purification. Seven plaque-purified phages were isolated that carried inserts hybridizing to the human MPL-K receptor probe. The phagemids contained within the λ

ExCellTM phage were recovered using the ⁴⁴ *in vivo* recombination system in accordance with the directions of the vendor. The identity of the cDNA inserts was confirmed by DNA sequencing.

5 The isolated clones encoded a protein exhibiting a high degree of sequence identity to human MPL-P receptor and to a recently reported mouse MPL receptor (Skoda et al., EMBO J. 12: 2645-2653, 1993). The seven clones fell into two classes differing from each other by three clones
10 having a deletion of sequences encoding a stretch of 60 amino acid residues near the N-terminus. The cDNA encoding the protein without the deletion was referred to as mouse Type I MPL receptor cDNA. Type II receptor cDNA lacked sequences encoding Type I receptor residues 131 to
15 190 of SEQ ID NO:8. In addition, Type I and II receptors differed from the reported mouse MPL receptor sequence (Skoda et al., *ibid.*) by the presence of a sequence encoding the amino acid residues Val-Arg-Thr-Ser-Pro-Ala-Gly-Glu (SEQ ID NO:9) inserted after amino acid residue
20 222 and by a substitution of a glycine residue for serine at position 241 (positions refer to the Type I mouse receptor).

 Type I and II mouse MPL receptor cDNAs were subcloned into the plasmid vector pHZ-1 for expression in
25 mammalian cells. Plasmid pHZ-1 is an expression vector that may be used to express protein in mammalian cells or in a frog oocyte translation system from mRNAs that have been transcribed *in vitro*. The pHZ-1 expression unit comprises the mouse metallothionein-1 promoter, the
30 bacteriophage T7 promoter flanked by multiple cloning banks containing unique restriction sites for insertion of coding sequences, the human growth hormone terminator and the bacteriophage T7 terminator. In addition, pHZ-1 contains an *E. coli* origin of replication; a bacterial
35 beta lactamase gene; a mammalian selectable marker expression unit comprising the SV40 promoter and origin, a

45

neomycin resistance gene and the SV40 transcription terminator. To facilitate directional cloning into pHZ-1, a polymerase chain reaction employing appropriate primers was used to create an *Eco* RI site upstream from the translation initiation codon and a *Xho* I site downstream from the translation termination codon. The polymerase chain reaction was carried out in a mixture containing 10 μ l 10x ULTMA™ DNA polymerase buffer (Roche Molecular Systems, Inc., Branchburg, NJ), 6 μ l of 25 mM $MgCl_2$, 0.2 μ l of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and dCTP (Pharmacia LKB Biotechnology Inc.), 2.5 μ l of 20 pmole/ μ l primer ZC6603 (SEQ ID NO:10), 2.5 μ l of 20 pmole/ μ l primer ZC5762 (SEQ ID NO:11), 32.8 μ l of water, 1 μ l of an early log phase bacterial culture harboring either a Type I or a Type II mouse MPL receptor plasmid and 1 μ l of 6 U/ μ l DNA polymerase (ULTMA™ polymerase; Roche Molecular Systems, Inc., Branchburg, NJ). AmpliWax™ (Roche Molecular Systems, Inc.) was employed in the reaction according to the directions of the vendor. The polymerase chain reaction was run for 25 cycles (1 minute at 95° C, 1 minute at 55° C and 3 minutes at 72° C) followed by a 10 minute incubation at 72° C. The amplified products were serially extracted with phenol/chloroform and chloroform, then ethanol precipitated in the presence of 6 μ g glycogen carrier and 2.5 M ammonium acetate. The pellets were resuspended in 87 μ l of water to which was added 10 μ l of 10 x H buffer (Boehringer Mannheim, Inc.), 2 μ l of 10 U/ μ l *Eco* RI (Boehringer Mannheim, Inc.) and 1 μ l of 40 U/ μ l *Xho* I (Boehringer Mannheim, Inc.). Digestion was carried out at 37° C for 1 hour. The reaction was terminated by heating to 65° C for 15 minutes and chromatographed through a 400 pore size gel filtration column (CHROMA SPIN + TE-400™; Clontech Laboratories Inc.).

The isolated receptor inserts described above were ligated into *Eco* RI and *Xho* I digested and

46

dephosphorylated pHZ-1 vector. The ligation reaction contained 1 μ l of 50 ng/ μ l prepared pHZ-1 vector, 5 μ l of 5 ng/ μ l cDNA insert, 2 μ l of 10x ligase buffer (Promega Corp.), 11.75 μ l water and 0.25 μ l of 4 U/ μ l T4 DNA ligase (Stratagene Cloning Systems). Ligation was carried out at 10° C overnight. The ligated DNAs were transfected into *E. coli* (MAX EFFICIENCY DH10B™ competent cells; GIBCO BRL) in accordance with the vendor's directions. The validity of Type I and Type II mouse *MPL* and human *MPL-P* receptor inserts in pHZ-1 was confirmed by DNA sequencing. The resulting plasmids pSLmpl-8 and pSLmpl-9 carried the mouse Type II and Type I *MPL* receptor cDNAs, respectively. Plasmid pSLmpl-44 carried the human *MPL-P* cDNA insert.

A mammalian expression plasmid encoding soluble mouse Type I *MPL* receptor (pLDmpl-53) was produced by combining DNA segments from pSLmpl-9, a mammalian expression plasmid containing the cDNA encoding full-length mouse Type I *MPL* receptor described above, with a DNA segment from pSLmpl-26, an expression plasmid constructed to produce the soluble mouse Type I *MPL* receptor in bacteria.

A cDNA segment encoding mouse Type I *MPL* soluble receptor was isolated by PCR employing primers ZC6704 (SEQ ID NO:12) and ZC6703 (SEQ ID NO:13) using full-length receptor plasmid pSLmpl-9 as template. To facilitate directional cloning, primers ZC6704 and ZC6703 incorporated *Eco* RI and *Xho* I restriction sites at their respective 5' ends. Primer ZC6703 also encoded an inframe consensus target sequence for protein kinase to enable *in vitro* labeling of the purified soluble receptor with ³²P γ -ATP (Li et al., Proc. Natl. Acad. Sci. U.S.A. 86: 558-562, 1989). The PCR was carried out in a mixture containing 10 μ l 10x ULTMA™ DNA polymerase buffer (Roche Molecular Systems, Inc.), 6 μ l of 25 mM MgCl₂, 0.2 μ l of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and dCTP (Pharmacia LKB

47

Biotechnology Inc.), 11 μ l of 4.55 pmole/ μ l primer ZC6704 (SEQ ID NO:12), 21 μ l of 2.43 pmole/ μ l primer ZC6703 (SEQ ID NO:13), 50.3 μ l of water, 1 μ l 50 ng/ μ l *Hind* III and *Xba* I digested pSLmpl-9 and 1 μ l of 6 U/ μ l ULTMA™ DNA polymerase (Roche Molecular Systems, Inc.). AmpliWax™ (Roche Molecular Systems, Inc.) was employed in the reaction according to the directions of the vendor. The polymerase chain reaction was run for 3 cycles (1 minute at 95° C, 1 minute at 50° C and 2 minutes at 72° C) followed by 11 cycles at increased hybridization stringency (1 minute at 95° C, 30 seconds at 55° C and 2 minutes at 72° C) followed by a 10 minute incubation at 72° C. The amplified product was serially extracted with phenol/chloroform and chloroform followed by chromatography through a 400 pore size gel filtration column (Clontech Laboratories, Inc.). The PCR product was ethanol precipitated in the presence of 20 μ g glycogen carrier and 2.5 M ammonium acetate. The pellet was resuspended in 32 μ l of water. To 16 μ l of the resuspended PCR product was added 2 μ l 10x H buffer (Boehringer Mannheim, Inc.), 1 μ l of 10 U/ μ l *Eco* RI (Boehringer Mannheim, Inc.) and 1 μ l of 40 U/ μ l *Xho* I (Boehringer Mannheim, Inc.). Digestion was carried out at 37° C for 1 hour. Digestion was terminated by heating to 65° C for 15 minutes, and DNA was purified on a 0.7% low-melt agarose gel. Fragment recovery from low-melt agarose was done by digestion of the gel matrix with β -agarase I (New England Biolabs).

The resulting PCR product encoded the N-terminal extracellular domain of mouse Type I MPL receptor (residues 27 to 480 of SEQ ID NO:8). In the absence of the putative receptor trans-membrane domain (residues 483 to 504 of SEQ ID NO:8) the expressed protein is expected to be secreted in the presence of a suitable signal peptide. A mouse Type II soluble MPL receptor encoding cDNA was obtained using the PCR conditions described above

48

except that pSLmpl-8 was used as template. The validity of both receptor fragments was confirmed by DNA sequencing.

The soluble mouse Type I and Type II MPL receptor encoding DNA fragments were cloned into *Eco* RI and *Xho* I digested vector pOmpA2-5 to yield pSLmpl-26 and pSLmpl-27, respectively. Plasmid pOmpA2-5 is a modification of pOmpA2 (Ghrayab et al., EMBO J. 3: 2437-2442, 1984), a bacterial expression vector designed to target the recombinant protein to the periplasmic space. pOmpA2-5 was constructed by replacement of a 13 bp sequence between the *Eco* RI and *Bam* HI sites of pOmpA2 with a synthetic 42 bp sequence. The sequence was created by annealing of two 42 nucleotide complementary oligonucleotides (ZC6707, SEQ ID NO:14; ZC 6706, SEQ ID NO:15), which when base paired formed *Eco* RI and *Bam* HI cohesive ends, facilitating directional cloning into *Eco* RI and *Bam* HI digested pOmpA2. Within the inserted sequence is an *Xho* I site inframe with respect to a bacterial leader sequence and to the mouse MPL soluble receptor encoding cDNAs described above, as well as an inframe tract of 6 histidine codons located 3' of the *Xho* I site to enable the recombinant protein to be purified by metal chelation affinity chromatography (Houchuli et al., Bio/Technol. 6: 1321-1325, 1988). Following the sequence encoding the histidine tract was an inframe termination codon. The validity of the pOmpA2-5, pSLmpl-26 and pSLmpl-27 was confirmed by DNA sequencing.

pLDmpl-53, a mammalian expression plasmid producing soluble mouse Type I MPL receptor, was constructed by combining DNA segments from pSLmpl-9 and pSLmpl-26 into expression vector pHZ-200 (pHZ-1 in which a dihydrofolate reductase sequence was substituted for the neomycin resistance gene). The 1164 bp *Eco* RI/*Bam* HI cDNA fragment from pSLmpl-9 replaced the mammalian signal sequence deleted during the construction of bacterial

49

expression plasmid pSLmpl-26. The 416 bp Bam HI fragment from pSLmpl-26 supplied the coding sequence for the carboxy-terminal portion of the soluble MPL receptor, the kinase labeling domain, the poly-histidine tract and the translation terminator. The two fragments were gel purified and cloned into the Eco RI/Bam HI sites of pBluescript® KS+ (Stratagene Cloning Systems) to yield plasmid pBS8.76LD-5. Correct orientation of the 416 bp pSLmpl-26 derived Bam HI fragment with respect to the 1164 bp pSLmpl-9 derived Eco RI/Bam HI fragment in pBS8.76LD-5 was determined by PCR using primers ZC 6603 (SEQ ID NO:10) and ZC 6703 (SEQ ID NO:13). The Xba I site within the poly-linker sequence of pBS8.76LD-5 enabled the reconstituted receptor cDNA to be excised as a 1.5 kb Eco RI/Xba I fragment for cloning into pHZ-200 following digestion of the vector with Eco RI and Xba I. The resulting mammalian expression plasmid, pLDmpl-53, was prepared in large scale for transfection into BHK cells.

Twenty micrograms of purified pLDmpl-53 plasmid was transfected into BHK 570 cells using the calcium phosphate precipitation method. After 5 hours, the cells were shocked with 15% glycerol for 3 minutes to facilitate uptake of DNA. Fresh growth media was added overnight. The following day the cells were split at various dilutions, and selection media containing 1 μ M methotrexate was added. After approximately two weeks, discrete, methotrexate-resistant colonies were visible. Resistant colonies were either pooled or maintained as distinct clones. Spent media from the pooled colonies was immediately tested for presence of soluble MPL receptor protein.

Soluble MPL receptor protein was isolated through the interaction of the poly-histidine tract present on the carboxy-terminal of the protein with a metal chelation resin containing immobilized Ni²⁺ (HIS-BIND™; Novagen, Madison, WI). Serum-free spent culture

media from the pLDmpl-53⁵⁰ pool was passed over the resin, and bound protein was eluted with 1 M imidazole. SDS-PAGE analysis revealed a single band at ~67 kDa. This protein was subjected to N-terminal amino acid analysis and
5 confirmed to be mouse MPL receptor.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various
10 modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

S/
SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle
WA
USA
98102
- (ii) TITLE OF INVENTION: LOW MOLECULAR WEIGHT THROMBOPOIETIN
- (iii) NUMBER OF SEQUENCES: 15
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: ZymoGenetics, Inc.
 - (B) STREET: 1201 Eastlake Avenue East
 - (C) CITY: Seattle
 - (D) STATE: WA
 - (E) COUNTRY: USA
 - (F) ZIP: 98102
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Parker, Gary E
 - (B) REGISTRATION NUMBER: 31-648
 - (C) REFERENCE/DOCKET NUMBER: 94-12PC
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 206-442-6673
 - (B) TELEFAX: 206-442-6678

52

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1486 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 105..1241

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|---|-----|
| CCTCGTGCCG GTCCTGAGGC CCTTCTCCAC CCGGACAGAG TCCTTGCCCC ACCTCTCTCC | 60 |
| CACCCGACTC TGCCGAAAGA AGCACAGAAG CTCAAGCCGC CTCC ATG GCC CCA GGA | 116 |
| Met Ala Pro Gly | |
| 1 | |
| AAG ATT CAG GGG AGA GGC CCC ATA CAG GGA GCC ACT TCA GTT AGA CAC | 164 |
| Lys Ile Gln Gly Arg Gly Pro Ile Gln Gly Ala Thr Ser Val Arg His | |
| 5 10 15 20 | |
| CTG GCC AGA ATG GAG CTG ACT GAT TTG CTC CTG GCG GCC ATG CTT CTT | 212 |
| Leu Ala Arg Met Glu Leu Thr Asp Leu Leu Leu Ala Ala Met Leu Leu | |
| 25 30 35 | |
| GCA GTG GCA AGA CTA ACT CTG TCC AGC CCC GTA GCT CCT GCC TGT GAC | 260 |
| Ala Val Ala Arg Leu Thr Leu Ser Ser Pro Val Ala Pro Ala Cys Asp | |
| 40 45 50 | |
| CCC AGA CTC CTA AAT AAA CTG CTG CGT GAC TCC CAC CTC CTT CAC AGC | 308 |
| Pro Arg Leu Leu Asn Lys Leu Leu Arg Asp Ser His Leu Leu His Ser | |
| 55 60 65 | |
| CGA CTG AGT CAG TGT CCC GAC GTC GAC CCT TTG TCT ATC CCT GTT CTG | 356 |
| Arg Leu Ser Gln Cys Pro Asp Val Asp Pro Leu Ser Ile Pro Val Leu | |
| 70 75 80 | |

| | | | | | | | | | | | | | | | | | | | |
|--|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | 53 | | | | | | | | | | | | | | | | | | |
| CTG CCT GCT GTG GAC TTT AGC CTG GGA GAA TGG AAA ACC CAG ACG GAA Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Thr Glu 85 90 95 100 | 404 | | | | | | | | | | | | | | | | | | |
| CAG AGC AAG GCA CAG GAC ATT CTA GGG GCA GTG TCC CTT CTA CTG GAG Gln Ser Lys Ala Gln Asp Ile Leu Gly Ala Val Ser Leu Leu Leu Glu 105 110 115 | 452 | | | | | | | | | | | | | | | | | | |
| GGA GTG ATG GCA GCA CGA GGA CAG TTG GAA CCC TCC TGC CTC TCA TCC Gly Val Met Ala Ala Arg Gly Gln Leu Glu Pro Ser Cys Leu Ser Ser 120 125 130 | 500 | | | | | | | | | | | | | | | | | | |
| CTC CTG GGA CAG CTT TCT GGG CAG GTT CGC CTC CTC TTG GGG GCC CTG Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 135 140 145 | 548 | | | | | | | | | | | | | | | | | | |
| CAG GGC CTC CTA GGA ACC CAG CTT CCT CTA CAG GGC AGG ACC ACA GCT Gln Gly Leu Leu Gly Thr Gln Leu Pro Leu Gln Gly Arg Thr Thr Ala 150 155 160 | 596 | | | | | | | | | | | | | | | | | | |
| CAC AAG GAC CCC AAT GCC CTC TTC TTG AGC TTG CAA CAA CTG CTT CGG His Lys Asp Pro Asn Ala Leu Phe Leu Ser Leu Gln Gln Leu Leu Arg 165 170 175 180 | 644 | | | | | | | | | | | | | | | | | | |
| GGA AAG GTG CGC TTC CTG CTT CTG GTA GAA GGT CCC ACC CTC TGT GTC Gly Lys Val Arg Phe Leu Leu Leu Val Glu Gly Pro Thr Leu Cys Val 185 190 195 | 692 | | | | | | | | | | | | | | | | | | |
| AGA CGG ACC CTG CCA ACC ACA GCT GTC CCA AGC AGT ACT TCT CAA CTC Arg Arg Thr Leu Pro Thr Thr Ala Val Pro Ser Ser Thr Ser Gln Leu 200 205 210 | 740 | | | | | | | | | | | | | | | | | | |
| CTC ACA CTA AAC AAG TTC CCA AAC AGG ACT TCT GGA TTG TTG GAG ACG Leu Thr Leu Asn Lys Phe Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr 215 220 225 | 788 | | | | | | | | | | | | | | | | | | |
| AAC TTC AGT GTC ACA GCC AGA ACT GCT GGC CCT GGA CTT CTG AGC AGG Asn Phe Ser Val Thr Ala Arg Thr Ala Gly Pro Gly Leu Leu Ser Arg 230 235 240 | 836 | | | | | | | | | | | | | | | | | | |
| CTT CAG GGA TTC AGA GTC AAG ATT ACT CCT GGT CAG CTA AAT CAA ACC Leu Gln Gly Phe Arg Val Lys Ile Thr Pro Gly Gln Leu Asn Gln Thr 245 250 255 260 | 884 | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|------------|------------|------------|-----|-----|-----|-----|-----|------|------|--|-----|
| 54 | | | | | | | | | | | | | | | | | | |
| TCC | AGG | TCC | CCA | GTC | CAA | ATC | TCT | GGA | TAC | CTG | AAC | AGG | ACA | CAC | GGA | 932 | | |
| Ser | Arg | Ser | Pro | Val | Gln | Ile | Ser | Gly | Tyr | Leu | Asn | Arg | Thr | His | Gly | | | |
| | | | | 265 | | | | | | 270 | | | | | | 275 | | |
| CCT | GTG | AAT | GGA | ACT | CAT | GGG | CTC | TTT | GCT | GGA | ACC | TCA | CTT | CAG | ACC | 980 | | |
| Pro | Val | Asn | Gly | Thr | His | Gly | Leu | Phe | Ala | Gly | Thr | Ser | Leu | Gln | Thr | | | |
| | | | | 280 | | | | | | 285 | | | | | | 290 | | |
| CTG | GAA | GCC | TCA | GAC | ATC | TCG | CCC | GGA | GCT | TTC | AAC | AAA | GGC | TCC | CTG | 1028 | | |
| Leu | Glu | Ala | Ser | Asp | Ile | Ser | Pro | Gly | Ala | Phe | Asn | Lys | Gly | Ser | Leu | | | |
| | | | | 295 | | | | | | 300 | | | | | | 305 | | |
| GCA | TTC | AAC | CTC | CAG | GGT | GGA | CTT | CCT | CCT | TCT | CCA | AGC | CTT | GCT | CCT | 1076 | | |
| Ala | Phe | Asn | Leu | Gln | Gly | Gly | Leu | Pro | Pro | Ser | Pro | Ser | Leu | Ala | Pro | | | |
| | | | | 310 | | | | | | 315 | | | | | | 320 | | |
| GAT | GGA | CAC | ACA | CCC | TTC | CCT | CCT | TCA | CCT | GCC | TTG | CCC | ACC | ACC | CAT | 1124 | | |
| Asp | Gly | His | Thr | Pro | Phe | Pro | Pro | Ser | Pro | Ala | Leu | Pro | Thr | Thr | His | | | |
| | | | | 325 | | | | | | 330 | | | | | | 335 | | 340 |
| GGA | TCT | CCA | CCC | CAG | CTC | CAC | CCC | CTG | TTT | CCT | GAC | CCT | TCC | ACC | ACC | 1172 | | |
| Gly | Ser | Pro | Pro | Gln | Leu | His | Pro | Leu | Phe | Pro | Asp | Pro | Ser | Thr | Thr | | | |
| | | | | 345 | | | | | | 350 | | | | | | 355 | | |
| ATG | CCT | AAC | TCT | ACC | GCC | CCT | CAT | CCA | GTC | ACA | ATG | TAC | CCT | CAT | CCC | 1220 | | |
| Met | Pro | Asn | Ser | Thr | Ala | Pro | His | Pro | Val | Thr | Met | Tyr | Pro | His | Pro | | | |
| | | | | 360 | | | | | | 365 | | | | | | 370 | | |
| AGG | AAT | TTG | TCT | CAG | GAA | ACA | TAGCGCGGGC | ACTGGCCCAG | TGAGCGTCTG | | | | | | | 1271 | | |
| Arg | Asn | Leu | Ser | Gln | Glu | Thr | | | | | | | | | | | | |
| | | | | 375 | | | | | | | | | | | | | | |
| CAGCTTCTCT | CGGGGACAAG | CTTCCCCAGG | AAGGCTGAGA | GGCAGCTGCA | TCTGCTCCAG | | | | | | | | | | | 1331 | | |
| ATGTTCTGCT | TTCACCTAAA | AGGCCCTGGG | GAAGGGATAC | ACAGCACTGG | AGATTGTAAA | | | | | | | | | | | 1391 | | |
| ATTTTAGGAG | CTATTTTTTT | TTAACCTATC | AGCAATATTC | ATCAGAGCAG | CTAGCGATCT | | | | | | | | | | | 1451 | | |
| TTGGTCTATT | TTCGGTATAA | ATTTGAAAAT | CACTA | | | | | | | | | | | | 1486 | | | |

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 379 amino acids

55

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Pro Gly Lys Ile Gln Gly Arg Gly Pro Ile Gln Gly Ala Thr
 1 5 10 15
 Ser Val Arg His Leu Ala Arg Met Glu Leu Thr Asp Leu Leu Leu Ala
 20 25 30
 Ala Met Leu Leu Ala Val Ala Arg Leu Thr Leu Ser Ser Pro Val Ala
 35 40 45
 Pro Ala Cys Asp Pro Arg Leu Leu Asn Lys Leu Leu Arg Asp Ser His
 50 55 60
 Leu Leu His Ser Arg Leu Ser Gln Cys Pro Asp Val Asp Pro Leu Ser
 65 70 75 80
 Ile Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys
 85 90 95
 Thr Gln Thr Glu Gln Ser Lys Ala Gln Asp Ile Leu Gly Ala Val Ser
 100 105 110
 Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu Glu Pro Ser
 115 120 125
 Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu
 130 135 140
 Leu Gly Ala Leu Gln Gly Leu Leu Gly Thr Gln Leu Pro Leu Gln Gly
 145 150 155 160
 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Leu Phe Leu Ser Leu Gln
 165 170 175
 Gln Leu Leu Arg Gly Lys Val Arg Phe Leu Leu Leu Val Glu Gly Pro
 180 185 190
 Thr Leu Cys Val Arg Arg Thr Leu Pro Thr Thr Ala Val Pro Ser Ser
 195 200 205

56

Thr Ser Gln Leu Leu Thr Leu Asn Lys Phe Pro Asn Arg Thr Ser Gly
 210 215 220

Leu Leu Glu Thr Asn Phe Ser Val Thr Ala Arg Thr Ala Gly Pro Gly
 225 230 235 240

Leu Leu Ser Arg Leu Gln Gly Phe Arg Val Lys Ile Thr Pro Gly Gln
 245 250 255

Leu Asn Gln Thr Ser Arg Ser Pro Val Gln Ile Ser Gly Tyr Leu Asn
 260 265 270

Arg Thr His Gly Pro Val Asn Gly Thr His Gly Leu Phe Ala Gly Thr
 275 280 285

Ser Leu Gln Thr Leu Glu Ala Ser Asp Ile Ser Pro Gly Ala Phe Asn
 290 295 300

Lys Gly Ser Leu Ala Phe Asn Leu Gln Gly Gly Leu Pro Pro Ser Pro
 305 310 315 320

Ser Leu Ala Pro Asp Gly His Thr Pro Phe Pro Pro Ser Pro Ala Leu
 325 330 335

Pro Thr Thr His Gly Ser Pro Pro Gln Leu His Pro Leu Phe Pro Asp
 340 345 350

Pro Ser Thr Thr Met Pro Asn Ser Thr Ala Pro His Pro Val Thr Met
 355 360 365

Tyr Pro His Pro Arg Asn Leu Ser Gln Glu Thr
 370 375

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1062 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

57

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1059

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | |
|---|-----|
| ATG GAG CTG ACT GAA TTG CTC CTC GTG GTC ATG CTT CTC CTA ACT GCA | 48 |
| Met Glu Leu Thr Glu Leu Leu Leu Val Val Met Leu Leu Leu Thr Ala | |
| 1 5 10 15 | |
| AGG CTA ACG CTG TCC AGC CCG GCT CCT CCT GCT TGT GAC CTC CGA GTC | 96 |
| Arg Leu Thr Leu Ser Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val | |
| 20 25 30 | |
| CTC AGT AAA CTG CTT CGT GAC TCC CAT GTC CTT CAC AGC AGA CTG AGC | 144 |
| Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser | |
| 35 40 45 | |
| CAG TGC CCA GAG GTT CAC CCT TTG CCT ACA CCT GTC CTG CTG CCT GCT | 192 |
| Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala | |
| 50 55 60 | |
| GTG GAC TTT AGC TTG GGA GAA TGG AAA ACC CAG ATG GAG GAG ACC AAG | 240 |
| Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys | |
| 65 70 75 80 | |
| GCA CAG GAC ATT CTG GGA GCA GTG ACC CTT CTG CTG GAG GGA GTG ATG | 288 |
| Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met | |
| 85 90 95 | |
| GCA GCA CGG GGA CAA CTG GGA CCC ACT TGC CTC TCA TCC CTC CTG GGG | 336 |
| Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly | |
| 100 105 110 | |
| CAG CTT TCT GGA CAG GTC CGT CTC CTC CTT GGG GCC CTG CAG AGC CTC | 384 |
| Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu | |
| 115 120 125 | |
| CTT GGA ACC CAG CTT CCT CCA CAG GGC AGG ACC ACA GCT CAC AAG GAT | 432 |
| Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp | |
| 130 135 140 | |

58

| | |
|---|-----|
| CCC AAT GCC ATC TTC CTG AGC TTC CAA CAC CTG CTC CGA GGA AAG GTG | 480 |
| Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val | |
| 145 150 155 160 | |
| CGT TTC CTG ATG CTT GTA GGA GGG TCC ACC CTC TGC GTC AGG CGG GCC | 528 |
| Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala | |
| 165 170 175 | |
| CCA CCC ACC ACA GCT GTC CCC AGC AGA ACC TCT CTA GTC CTC ACA CTG | 576 |
| Pro Pro Thr Thr Ala Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu | |
| 180 185 190 | |
| AAC GAG CTC CCA AAC AGG ACT TCT GGA TTG TTG GAG ACA AAC TTC ACT | 624 |
| Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr | |
| 195 200 205 | |
| GCC TCA GCC AGA ACT ACT GGC TCT GGG CTT CTG AAG TGG CAG CAG GGA | 672 |
| Ala Ser Ala Arg Thr Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly | |
| 210 215 220 | |
| TTC AGA GCC AAG ATT CCT GGT CTG CTG AAC CAA ACC TCC AGG TCC CTG | 720 |
| Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu | |
| 225 230 235 240 | |
| GAC CAA ATC CCC GGA TAC CTG AAC AGG ATA CAC GAA CTC TTG AAT GGA | 768 |
| Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly | |
| 245 250 255 | |
| ACT CGT GGA CTC TTT CCT GGA CCC TCA CGC AGG ACC CTA GGA GCC CCG | 816 |
| Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro | |
| 260 265 270 | |
| GAC ATT TCC TCA GGA ACA TCA GAC ACA GGC TCC CTG CCA CCC AAC CTC | 864 |
| Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu | |
| 275 280 285 | |
| CAG CCT GGA TAT TCT CCT TCC CCA ACC CAT CCT CCT ACT GGA CAG TAT | 912 |
| Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr | |
| 290 295 300 | |
| ACG CTC TTC CCT CTT CCA CCC ACC TTG CCC ACC CCT GTG GTC CAG CTC | 960 |
| Thr Leu Phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu | |
| 305 310 315 320 | |

CAC CCC CTG CTT CCT GAC CCT TCT GCT CCA ACG CCC ACC CCT ACC AGC 1008
 His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser
 325 330 335
 CCT CTT CTA AAC ACA TCC TAC ACC CAC TCC CAG AAT CTG TCT CAG GAA 1056
 Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu
 340 345 350
 GGG TAA 1062
 Gly

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 353 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Glu Leu Thr Glu Leu Leu Leu Val Val Met Leu Leu Leu Thr Ala
 1 5 10 15
 Arg Leu Thr Leu Ser Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val
 20 25 30
 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser
 35 40 45
 Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala
 50 55 60
 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys
 65 70 75 80
 Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met
 85 90 95
 Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly
 100 105 110

60

Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu
115 120 125

Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp
130 135 140

Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val
145 150 155 160

Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala
165 170 175

Pro Pro Thr Thr Ala Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu
180 185 190

Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr
195 200 205

Ala Ser Ala Arg Thr Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly
210 215 220

Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu
225 230 235 240

Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly
245 250 255

Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro
260 265 270

Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu
275 280 285

Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr
290 295 300

Thr Leu Phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu
305 310 315 320

His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser
325 330 335

Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu
340 345 350

Gly

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (B) CLONE: ZC8045

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGAAGTCCTG TTTGAATTCT AGTTCAGTGT GAGGACATTA AGA

43

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (B) CLONE: ZC7878

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCGTCTCCTC CTTGGGGCCC ATTAAGA

27

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid

62

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC6091

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GAGCACAGAA TTCACTACTC GAGGCGGCCG CTTTTTTTTT TTTTTTTT

49

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 633 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala
1 5 10 15

Leu Pro Asn Gln Ala Gln Val Thr Ser Gln Asp Val Phe Leu Leu Ala
20 25 30

Leu Gly Thr Glu Pro Leu Asn Cys Phe Ser Gln Thr Phe Glu Asp Leu
35 40 45

Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln
50 55 60

Leu Leu Tyr Ala Tyr Arg Gly Glu Lys Pro Arg Ala Cys Pro Leu Tyr
65 70 75 80

Ser Gln Ser Val Pro Thr Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro
85 90 95

Ala Gln Asp Glu Val Arg Leu Phe Phe Pro Leu His Leu Trp Val Lys
100 105 110

63

Asn Val Ser Leu Asn Gln Thr Leu Ile Gln Arg Val Leu Phe Val Asp
 115 120 125

Ser Val Gly Leu Pro Ala Pro Pro Arg Val Ile Lys Ala Arg Gly Gly
 130 135 140

Ser Gln Pro Gly Glu Leu Gln Ile His Trp Glu Ala Pro Ala Pro Glu
 145 150 155 160

Ile Ser Asp Phe Leu Arg His Glu Leu Arg Tyr Gly Pro Thr Asp Ser
 165 170 175

Ser Asn Ala Thr Ala Pro Ser Val Ile Gln Leu Leu Ser Thr Glu Thr
 180 185 190

Cys Cys Pro Thr Leu Trp Met Pro Asn Pro Val Pro Val Leu Asp Gln
 195 200 205

Pro Pro Cys Val His Pro Thr Ala Ser Gln Pro His Gly Pro Val Arg
 210 215 220

Thr Ser Pro Ala Gly Glu Ala Pro Phe Leu Thr Val Lys Gly Gly Ser
 225 230 235 240

Cys Leu Val Ser Gly Leu Gln Ala Gly Lys Ser Tyr Trp Leu Gln Leu
 245 250 255

Arg Ser Gln Pro Asp Gly Val Ser Leu Arg Gly Ser Trp Gly Pro Trp
 260 265 270

Ser Phe Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val Thr Ile Gly
 275 280 285

Leu Gln Cys Phe Thr Leu Asp Leu Lys Met Val Thr Cys Gln Trp Gln
 290 295 300

Gln Gln Asp Arg Thr Ser Ser Gln Gly Phe Phe Arg His Ser Arg Thr
 305 310 315 320

Arg Cys Cys Pro Thr Asp Arg Asp Pro Thr Trp Glu Lys Cys Glu Glu
 325 330 335

Glu Glu Pro Arg Pro Gly Ser Gln Pro Ala Leu Val Ser Arg Cys His
 340 345 350

64

Phe Lys Ser Arg Asn Asp Ser Val Ile His Ile Leu Val Glu Val Thr
 355 360 365

Thr Ala Gln Gly Ala Val His Ser Tyr Leu Gly Ser Pro Phe Trp Ile
 370 375 380

His Gln Ala Val Leu Leu Pro Thr Pro Ser Leu His Trp Arg Glu Val
 385 390 395 400

Ser Ser Gly Arg Leu Glu Leu Glu Trp Gln His Gln Ser Ser Trp Ala
 405 410 415

Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly Glu Gly Arg Glu
 420 425 430

Asp Trp Lys Val Leu Glu Pro Ser Leu Gly Ala Arg Gly Gly Thr Leu
 435 440 445

Glu Leu Arg Pro Arg Ala Arg Tyr Ser Leu Gln Leu Arg Ala Arg Leu
 450 455 460

Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ala Trp Ser Pro Pro Ala
 465 470 475 480

Arg Val Ser Thr Gly Ser Glu Thr Ala Trp Ile Thr Leu Val Thr Ala
 485 490 495

Leu Leu Leu Val Leu Ser Leu Ser Ala Leu Leu Gly Leu Leu Leu Leu
 500 505 510

Lys Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu Trp
 515 520 525

Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg Asp
 530 535 540

Thr Ala Ala Leu Ser Pro Ser Lys Ala Thr Val Thr Asp Ser Cys Glu
 545 550 555 560

Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu Ser
 565 570 575

Thr Pro Leu Pro Leu Cys Pro Ser Gln Pro Gln Met Asp Tyr Arg Gly
 580 585 590

65

Leu Gln Pro Cys Leu Arg Thr Met Pro Leu Ser Val Cys Pro Pro Met
 595 600 605

Ala Glu Thr Gly Ser Cys Cys Thr Thr His Ile Ala Asn His Ser Tyr
 610 615 620

Leu Pro Leu Ser Tyr Trp Gln Gln Pro
 625 630

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Val Arg Thr Ser Pro Ala Gly Glu
 1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (B) CLONE: ZC6603

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAGGAATTCG CAGAAGCCAT GCCCTCTTGG GCCCTCTTCA TGGTC

66

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 52 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC5762

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGAGAGAGAG AGAGCTCGAG TCAAGGCTGC TGCCAATAGC TTAGTGGTAG GT

52

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6704

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAAGAGGAAT TCACCATGGA TGTCTTCTTG CTGGCCTTGG GCACAGAG

48

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6703

67

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGACTTTACC TCGAGTGCTA CTGATGCTCT TCTGCCAGCA GTCTCGGAGC CCGTGGACAC 60

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6707

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AATTCGCCAT GGGACTCGAG CATCACCATC ACCATCACTG AG 42

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6706

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GATCCTCAGT GATGGTGATG GTGATGCTCG AGTCCCATGG CG 42

68

Claims

We claim:

1. An isolated mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d).

2. An isolated mammalian thrombopoietin according to claim 1, further characterized by:

a) a peptide backbone mass of 17,490 to 19,045 amu as determined by mass spectrometry;

b) absence of N-linked carbohydrate;

c) presence of O-linked carbohydrate; and

d) essentially free of thrombopoietin species having a peptide backbone mass greater than 19045 amu as determined by mass spectrometry.

3. An isolated mammalian thrombopoietin according to claim 1 having an amino acid sequence consisting of:

(a) the sequence shown in SEQ ID NO:2 from an amino-terminus at Ser, residue number 45, to a carboxyl-

terminus between Ser, residue number 208, and Asn, residue number 216, inclusive; or

(b) a sequence which is an allelic variant of (a).

4. An isolated mammalian thrombopoietin according to claim 1 characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid sequence which is an allelic variant of (a).

5. A purified mammalian thrombopoietin according to claim 1 which is a mixture of polypeptides having different carboxyl termini.

6. A composition of mammalian thrombopoietin consisting essentially of one or more polypeptides having an amino acid sequence consisting of:

(a) the sequence shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; and

(b) allelic variants of (a).

7. A composition according to claim 6 wherein said one or more polypeptides are further characterized by an absence of N-linked carbohydrate and a presence of O-linked carbohydrate.

8. A composition of mammalian thrombopoietin consisting essentially of one or more polypeptides having an amino acid sequence selected from the group consisting of:

70

(a) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(c) allelic variants of (a) and (b).

9. A pharmaceutical composition comprising a thrombopoietin polypeptide in combination with a pharmaceutically acceptable vehicle, wherein said thrombopoietin polypeptide is characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d).

10. A pharmaceutical composition according to claim 9 wherein said thrombopoietin polypeptide is further characterized by:

a) a peptide backbone mass of 17,490 to 19,045 amu as determined by mass spectrometry;

b) absence of N-linked carbohydrate;

c) presence of O-linked carbohydrate, and said composition is essentially free of thrombopoietin species

having a peptide backbone mass ⁷¹greater than 19,045 amu as determined by mass spectrometry.

11. A pharmaceutical composition according to claim 9 wherein said thrombopoietin polypeptide is characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 having an amino-terminus at Ser, residue number 22, and a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid sequence which is an allelic variant of (a).

12. A pharmaceutical composition according to claim 9 wherein said thrombopoietin polypeptide is characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(c) allelic variants of (a) and (b).

13. A pharmaceutical composition according to claim 9 further comprising erythropoietin.

14. A method of stimulating platelet production in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of thrombopoietin in combination with a pharmaceutically acceptable vehicle, wherein said thrombopoietin is characterized by an amino acid sequence selected from the group consisting of:

72

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and.

(e) allelic variants of (a)-(d).

15. A method according to claim 14 wherein said thrombopoietin is further characterized by:

a) a peptide backbone mass of 17,490 to 19,405 amu as determined by mass spectrometry;

b) absence of N-linked carbohydrate;

c) presence of O-linked carbohydrate; and

d) essentially free of thrombopoietin species having a peptide backbone mass greater than 19,045 amu as determined by mass spectrometry.

16. A method according to claim 14 wherein said thrombopoietin is characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 having an amino-terminus at Ser, residue number 22, and a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid sequence which is an allelic variant of (a).

17. A method according to claim 14 wherein said thrombopoietin is characterized by an amino acid sequence selected from the group consisting of:

73

(a) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(c) allelic variants of (a) and (b).

18. A method according to claim 14 wherein said mammal is anemic and said method further comprises administering to said mammal an amount of erythropoietin effective to increase erythropoiesis.

19. An isolated DNA molecule encoding a mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d).

20. An isolated DNA molecule according to claim 19 wherein said thrombopoietin is characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid ⁷⁴sequence which is an allelic variant of (a).

21. An expression vector comprising a first DNA segment encoding a mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d),
wherein said first DNA segment is operably linked to one or more additional DNA segments that provide for its transcription.

22. An expression vector according to claim 21 wherein said thrombopoietin is characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid sequence which is an allelic variant of (a).

23. A cultured eukaryotic cell containing an expression vector comprising a first DNA segment encoding

75

a mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d),

wherein said first DNA segment is operably linked to one or more additional DNA segments that provide for its transcription.

24. A cultured eukaryotic cell according to claim 23 wherein said thrombopoietin is characterized by:

(a) an amino acid sequence as shown in SEQ ID NO:4 from an amino-terminus at Ser, residue number 22, to a carboxyl-terminus between Arg, residue number 185, and Asn, residue number 193, inclusive; or

(b) an amino acid sequence which is an allelic variant of (a).

25. A cultured eukaryotic cell according to claim 23 which is a yeast cell.

26. A cultured eukaryotic cell according to claim 23 which is a mammalian cell.

27. A cultured eukaryotic cell according to claim 26 which is a rodent cell.

76

28. A method for producing a mammalian thrombopoietin comprising the steps of:

culturing a eukaryotic cell containing an expression vector comprising a first DNA segment encoding a mammalian thrombopoietin characterized by an amino acid sequence selected from the group consisting of:

(a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive;

(b) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive;

(c) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198);

(d) a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and

(e) allelic variants of (a)-(d),
wherein said first DNA segment is operably linked to a second DNA segment encoding a secretory peptide and one or more additional DNA segments that provide for transcription of the first and second DNA segments, and wherein said cell expresses said first and second DNA segments and said thrombopoietin is secreted from the cell; and

selectively recovering said thrombopoietin.

1/2




Fig. 1

2/2




Fig. 2

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 95/14929

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/19 C12N15/79 C07K14/52 A61K38/19 C12N1/19
C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-------------------------------------|
| A | NATURE, vol. 369, no. 6481, 16 June 1994 LONDON GB, pages 565-568, SI LOK ET AL. 'Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo' cited in the application see the whole document --- -/-- | 1,6-9, 14,19, 21,23, 26-28 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

15 March 1996

Date of mailing of the international search report

27. 03. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 95/14929

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|---------------------------|
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| P,X | EP,A,0 675 201 (AMGEN INC) 4 October 1995 see page 3, line 3 - line 7 see page 7, line 34 - line 40 see page 8, line 13 - line 15 see page 8, line 30 - line 50 see page 9, line 28 - line 39 see page 11, line 16 - page 12, line 16 see page 14, line 16 - line 30 see page 14, line 42 - page 15, line 30 see page 15, line 41 - line 57 --- | 1,4-9, 11-14, 16-28 |
| T | J. BIOCHEM. (TOKYO) (1995), 118(1), 229-36 CODEN: JOBIAO;ISSN: 0021-924X, 1995 KATO, TAKASHI ET AL 'Purification and characterization of thrombopoietin' ----- | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 14929

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-18
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although these claims are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/14929

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|----------------------------------|
| EP-A-0675201 | 04-10-95 | AU-B- 2230895 EP-A- 0690127 WO-A- 9526746 | 23-10-95 03-01-96 12-10-95 |
| ----- | | | |